NZ516918A

NZ516918A - Caspase inhibitors and uses thereof

Info

Publication number: NZ516918A
Application number: NZ516918A
Authority: NZ
Inventors: Julian Golec
Original assignee: Vertex Pharma
Priority date: 2000-05-23
Filing date: 2001-05-23
Publication date: 2004-06-25
Also published as: PE20020058A1; AR028619A1; SK1192002A3; US20020061853A1; US7053057B2; NO20020343L; EP1283827A2; CA2380935A1; TR200200767T1; JP2003534325A; AU2001265008A1; WO2001090070A3; AP2002002407A0; NO20020343D0; KR20020025959A; MXPA02000823A; WO2001090070A2; PL357713A1

Abstract

A compound of formula I is described wherein: Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R1 is H, CHN2, R, or CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group or a heterocyclylalkyl group; Y is an electronegative leaving group, R2 is CO2H, CH2CO2H or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and R3 is H, an optionally substituted C1-6 alkyl, F2, CN, aryl or R3 is attached to Ar to form an unsaturated or partially saturated 5 or 6 membered fused ring having 0-2 heteroatoms; provided that if Ring A is unsubstituted piperidine; Ar is unsubstituted phenyl, R2 is CO2H or CO2-t-Bu; R3 is H then R1 is not -CH2-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl, and provided that R1 is not -(CH2)n-(Tet), wherein n is 1-4 and Tet is an optionally substituted tetrazole. The compounds can be used in the manufacturing of a medicament for treating a condition that is alleviated by treatment with a caspase inhibitor such as IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs host disease, organ transplant rejection, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kapos's sarcoma, multiple myeloma, haemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, or Japanese encephalitis, various forms of liver disease including alcoholic hepatitis, renal disease, polyaptic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, meningitis, complications associated with coronary artery bypass grafts, preservation of cells, preserving blood products and as a component of immunotherapy for the treatment of cancer.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 516918 5169 WO 01/90070 PCT/US01/17075 CASPASE INHIBITORS AND USES THEREOF This application claims the benefit of US provisional patent application serial number 60/206,362 filed May 23, 2000 and US provisional patent application serial number 60/217,006 filed July 10, 2000. Field of the Invention This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions thereof, that inhibit 5 caspases that mediate cell apoptosis and inflammation. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat diseases where caspase activity is implicated. 10 Background of the Invention Apoptosis, or programmed cell death, is a principal mechanism by which organisms eliminate unwanted cells. The deregulation of apoptosis, either excessive apoptosis or the failure to undergo it, has been 15 implicated in a number of diseases such as cancer, acute inflammatory and autoimmune disorders, ischemic diseases and certain neurodegenerative disorders (see generally Science, 1998, 281, 1283-1312; Ellis et al., Ann. Rev. Cell. Biol., 1991, 7, 663). 20 Caspases are a family of cysteine protease enzymes that are key mediators in the signaling pathways for'apoptosis and cell disassembly (Thornberry, Chem. -1- WO 01/90070 PCT/US01/17075 Biol., 1998, 5, R97-R103). These signaling pathways vary depending on cell type and stimulus, but all apoptosis pathways appear to converge at a common effector pathway leading to proteolysis of key proteins. Caspases are 5 involved in both the effector phase of the signaling pathway and further upstream at its initiation. The upstream caspases involved in initiation events become activated and in turn activate other caspases that are involved in the later phases of apoptosis. 10 Caspase-1, the first identified caspase, is also known as interleukin converting enzyme or ""ICE." Caspase-1 converts precursor interleukin-ip (*pIL-lJ3") to the pro-inflammatory active form by specific cleavage of ,pIL-ip between Asp-116 and Ala-117. Besides caspase-1 15 there are also eleven other known human caspases, all of which cleave specifically at aspartyl residues. They are also observed to have stringent requirements for at least four amino acid residues on the N-terminal side of the cleavage site. 20 The caspases have been classified into three groups depending on the amino acid sequence that is preferred or primarily recognized. The group of caspases, which includes caspases 1, 4, and 5, has been shown to prefer hydrophobic aromatic amino acids at position 4 on 25 the N-terminal side of the cleavage site. Another group which includes caspases 2, 3 and 7, recognize aspartyl residues at both positions 1 and 4 on the N-terminal side of the cleavage site, and preferably a sequence of Asp-Glu-X-Asp. A third group, which includes caspases 6, 30 8, 9 and 10, tolerate many amino acids in the primary recognition sequence, but seem to prefer residues with -2- WO 01/90070 PCT/US01/17075 branched, aliphatic side chains such as valine and leucine at position 4. The caspases have also been grouped according to their perceived function. The first subfamily consists 5 of caspases-1 (ICE), 4, and 5. These caspases have been shown to be involved in pro-inflammatory cytokine processing and therefore.play an important role in inflammation. Caspase-1, the most studied enzyme of this class, activates the IL-ip precursor by proteolytic 10 cleavage. This enzyme therefore plays a key role in the inflammatory response. Caspase-1 is also involved in the processing of interferon gamma inducing factor (IGIF or IL-18) which stimulates the production of interferon gamma, a key immunoregulator that modulates antigen 15 presentation, T-cell activation and cell adhesion. The remaining caspases make up the second and third subfamilies. These enzymes are of central importance in the intracellular signaling pathways leading to apoptosis. One subfamily consists of the 20 enzymes involved in initiating events in the apoptotic pathway, including transduction of signals from the plasma membrane. Members of this subfamily include caspases-2, 8, 9 and 10. The other subfamily, consisting of the effector capsases 3, 6 and 7, are involved in the 25 final downstream cleavage events that result in the systematic breakdown and death of the cell by apoptosis. Caspases involved in the upstream signal transduction activate the downstream caspases, which then disable DNA repair mechanisms, fragment DNA, dismantle the cell 30 cytoskeleton and finally fragment the cell. Knowledge of the four amino acid sequences primarily recognized by the caspases has been used to WO 01/90070 PCT/USO1/17075 design caspase inhibitors. Reversible tetrapeptide inhibitors have been prepared having the structure CH3CO- [P4] - [P3] - [P2] -CH (R) CH2CO2H where P2 to P4 represent an optimal amino acid recognition sequence and R is an 5 aldehyde, nitrile or ketone capable of binding to the caspase cysteine sulfhydryl. Rano and Thornberry, Chem. Biol. 4, 149-155 (1997); Mjalli, et al., Bioorg. Med. Chem. Lett. 3, 2689-2692 (1993); Nicholson et al., Nature 376, 37-43 (1995). Irreversible inhibitors based on the 10 analogous tetrapeptide recognition sequence have been prepared where R is an acyloxymethylketone -COCH2OCOR' . R' is exemplified by an optionally substituted phenyl such as 2,6-dichlorobenzoyloxy and where R is C0CH2X where X is a leaving group such as F or Cl. Thornberry et al., 15 Biochemistry 33, 3934 (1994); Dolle et al., J Med. Chem. 37, 563-564 (1994). The utility of caspase inhibitors to treat a variety of mammalian disease states associated with an increase in cellular apoptosis has been demonstrated 20 using peptidic caspase inhibitors. For example, in rodent models, caspase inhibitors have been shown to reduce infarct size and inhibit cardiomyocyte apoptosis after myocardial infarction, to reduce lesion volume and neurological deficit resulting from stroke, to reduce 25 post-traumatic apoptosis and neurological deficit in traumatic brain injury, to be effective in treating fulminant liver destruction, and to improve survival after endotoxic shock. Yaoita et al., Circulation, 97, 276 (1998); Endres et al., J Cerebral Blood Flow and 30 Metabolism, 18, 238, (1998); Cheng et al., J. Clin. Invest., 101, 1992 (1998); Yakovlev et al., J Neuroscience, 17, 7415 (1997); Rodriquez et al., J. Exp. -4- WO 01/90070 PCT/USO1/17075 Med., 184, 2067 (1996); Grobmyer et al., Mol. Med., 5, 585 (1999). In general, the peptidic inhibitors described above are very potent against some of the caspase 5 enzymes. However, this potency has not always been reflected in cellular models of apoptosis. In addition peptide inhibitors are typically characterized by undesirable pharmacological properties such as poor oral absorption, poor stability and rapid metabolism. 10 Plattner and Norbeck, in Drug Discovery Technologies, Clark and Moos, Eds. (Ellis Horwood, Chichester, England, 1990). The unsuitable pharmacological properties of the tetra- and tri-peptidic caspase inhibitors has 15 brought about the development of natural and non-natural amino acid di-peptidic inhibitors of caspases. WO 91/15577 and WO 93/05071 disclose peptide ICE inhibitors of the formula: Z-Qz-Asp-Qi 20 wherein Z is an N-terminal protecting group; Q2 is 0 to 4 amino acids; and Qi is an electronegative leaving group. However, WO 91/15577 only reports these compounds to be active against caspase-1 and does not report activity against other caspases. 25 WO 99/18781 discloses dipeptide caspase inhibitors of the formula: /CO, R, wherein Ri is an N-terminal protecting group; M is a residue of a natural a-amino acid, or p-amino acid;- R2 is -5- WO 01/90070 PCT/US01/17075 H or CH2R4 where R4 is an electronegative leaving group; and R3 is alkyl or H. WO 99/47154 discloses dipeptide caspase inhibitors of the formula: wherein Ri is an N-terminal protecting group; AA is a residue of a non-natural ot-amino acid, or 3~amino acid; and R2 is optionally substituted alkyl or H. WO 00/61542 discloses dipeptide apoptosis 10 inhibitors having the formula: O u O where Ri is an optionally substituted alkyl or hydrogen group; R2 is hydrogen or optionally substituted alkyl; Y 15 is a residue of a natural or non-natural amino acid and R3 is an alkyl, saturated carbocyclic, partially saturated carbocyclic, aryl, saturated heterocyclic, partially saturated heterocyclic or heteroaryl group, wherein said group is optionally substituted; X is 0, S, NR4/ or 20 (CR4R5) n where R4 and R5 are, at each occurrence, independently selected from the group consisting of hydrogen, alkyl and cycloalkyl, and n is 0, 1, 2, or 3; or X is NR4, and R3 and R4 are taken together with the nitrogen atom to which they are attached to form a 25 saturated heterocyclic, partially saturated heterocyclic or heteroaryl group, wherein said group is optionally substituted or X is CR4R5/ and R3 and R4 are taken together 5 6 WO 01/90070 PCT/US01/17075 with the carbon atom to which they are attached to form a saturated carbocyclic, partially saturated carbocyclic, aryl, saturated heterocyclic, partially saturated heterocyclic or oxygen-containing heteroaryl group, 5 wherein said group is optionally substituted; and provided that when X is 0, then R3 is not unsubstituted benzyl or t-butyl; and when X is CH2, then R3 is not H. reported, it is not clear whether they possess the 10 appropriate pharmacological properties to be therapeutically useful. Therefore, there is a continued need for small molecule caspase inhibitors that are potent, stable, and penetrate membranes to provide effective inhibition of apoptosis in vivo. Such 15 compounds would be extremely useful in treating the aforementioned diseases where caspase enzymes play a role. 20 invention and pharmaceutical compositions thereof are particularly effective as inhibitors of caspases and cellular apoptosis. These compounds have the general formula I: 25 wherein: Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; -7- While a number of caspase inhibitors have been Summary of the Invention It has now been found that compounds of this WO 01/90070 PCT/US01/17075 R1 is hydrogen, CHN2, R, or -CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or an heterocyclylalkyl group; 5 Y is an electronegative leaving group; R2 is C02H, CH2C02H, or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and R3 is hydrogen, an optionally substituted Ci_6 alkyl, F2, 10 CN, aryl or R3 is attached to Ar to form an unsaturated or partially saturated five or six membered fused ring having 0-2 heteroatoms. The compounds of this invention have potent inhibition properties across a range of caspase targets 15 with good efficacy in cellular models of apoptosis. In addition, these compounds are expected to have improved cell penetration and pharmacokinetic properties and, as a consequence of their potency, have improved efficacy against diseases where caspases are implicated. -8- WO 01/90070 PCT/US01/17075 Detailed Description of the Invention This invention provides novel compounds, and pharmaceutically acceptable derivatives thereof, that are particularly effective as caspase inhibitors. The 5 invention also provides methods for using the compounds to treat caspase-mediated disease states in mammals. The compounds have the general formula I: wherein: 10 Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R1 is hydrogen, CHN2, R, or -CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a 15 heterocyclic group, or an heterocyclylalkyl group; Y is an electronegative leaving group; R2 is C02H, CH2C02H, or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and 20 R3 is hydrogen, an optionally substituted Ci_6 alkyl, F2, CN, aryl or R3 is attached to Ar to form an unsaturated or partially saturated five or six membered fused ring having 0-2 heteroatoms. As used herein, the following definitions shall 25 apply unless otherwise indicated. The term '"aliphatic" as used herein means straight chained or branched Ci~Ci2 hydrocarbons which are completely saturated or which contain one or more units of unsaturation. Aliphatic groups include substituted or unsubstituted linear, -9- WO 01/90070 PCT/USO1/17075 branched or cyclic alkyl, alkenyl, or alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl) alkyl or .(cycloalkyl) alkenyl. The term 'aliphatic" includes *carbocyclic" groups. The term 5 "alkyl" used alone or as part of a larger moiety refers to both straight and branched chains containing one to twelve carbon atoms. When the term alkyl is used as part of a larger moiety, as in aralkyl or heteroaralkyl, the alkyl portion will preferably contain one to six carbons. 10 The term "halogen" means F, CI, Br, or I. The term ^heteroatom" means nitrogen, oxygen or sulfur. The term 'aryl" refers to monocyclic or polycyclic aromatic groups, and monocyclic or polycyclic heteroaromatic groups containing one or more heteroatoms, 15 having five to fourteen atoms. Such groups include, but are not restricted to phenyl, naphthyl, anthryl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, 20 pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-25 naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydrofuranyl, phthalimidinyl, tetrazolyl, and chromanyl. The term wheterocyclic group" refers to 30 saturated and unsaturated monocyclic or polycyclic ring systems containing one or more heteroatoms and a ring size of three to eight. Such groups include, but are not -10- WO 01/90070 PCT/US01/17075 limited to aziranyl, oxiranyl, azetidinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, pyranyl, piperidinyl, dioxanyl, morphol'inyl, dithianyl, 5 thiomorpholinyl, piperazinyl, trithianyl, quinuclidinyl, oxepanyl, and thiepanyl. The term 'carbocyclic group" refers to saturated monocyclic or polycyclic carbon ring systems which may be fused to aryl or heterocyclic groups. 10 Examples could include cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, indanyl, tetrahydronaphthyl and the like. An aliphatic, aryl, or heterocyclyl group may contain one or more substituents. Examples of suitable 15 substituents include a halogen, -R, -OR, -OH, -SH, -SR, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -N02, -CN, -NH2, -NHR, -N(R)2, -NHCOR, -NHCONHR, -NHCON(R)2, -NRCOR, -NHCO2R, -C02R, -C02H, -COR, -CONHR, -CON(R)2, -S(0)2R, -SONH2, 20 -S(0)R, -S02NHR, -NHS(0)2R/ =0, =S, =NNHR, =NNR2, =N-OR, =NNHCOR, =NNHC02R, =NNHS02R, or =NR where R is an aliphatic group or a substituted aliphatic group. A substitutable nitrogen on a heterocyclic ring may be optionally substituted. Suitable substituents on 25 the nitrogen include R, COR, S(0)2R, and C02R, where R is an aliphatic group or a substituted aliphatic group. Nitrogen and sulfur may be in their oxidized form, and nitrogen may be in a quaternized form. The term 'electronegative leaving group" has 30 the definition known to those skilled in the art (see March, Advanced Organic Chemistry, 4th Edition, John Wiley & Sons, 1992). Examples of electronegative leaving -11- WO 01/90070 PCT/USO1/17075 groups include halogens such as F, CI, Br, I, aryl- and alkylsulfonyloxy groups, trifluoromethanesulfonyloxy, OR, SR, -0C=0(R), -OPO(R4) (R5), where R is an aliphatic group, an aryl group, an aralkyl group, a carbocyclic group, an 5 alkyl carbocyclic group, a heterocyclic group, or an alkyl heterocyclic group; and R4 and R5 are independently selected from R or OR. When the R2 group is in the form of an ester or amide, the present compounds undergo metabolic cleavage 10 to the corresponding carboxylic acids, which are the active caspase inhibitors. Because they undergo metabolic cleavage, the precise nature of the ester or amide group is not critical to the working of this invention. The structure of the R2 group may range from 15 the relatively simple diethyl amide to a steroidal ester. Examples of esters of R2 carboxylic acids include, but are not limited to, C1-12 aliphatic, such as C1-6 alkyl or C3-10 cycloalkyl, aryl, such as phenyl, aralkyl, such as benzyl or phenethyl, heterocyclyl or heterocyclylalkyl. 20 Examples of suitable R2 heterocyclyl rings include, but are not limited to, 5-6 membered heterocyclic rings having one or two heteroatoms such as piperidinyl, piperazinyl, or morpholinyl. Amides of R2 carboxylic acids may be primary, 25 secondary or tertiary. Suitable substituents on the amide nitrogen include, but are not limited to, one or more groups independently selected from the aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl groups described above for the R2 ester alcohol. Likewise, other 30 prodrugs are included within the scope of this invention. See Bradley D. Anderson, "Prodrugs for Improved CNS -12- WO 01/90070 PCT/US01/17075 Delivery" in Advanced Drug Delivery Reviews (1996), 19, 171-202. Isosteres or bioisosteres of carboxylic acids and esters result from the exchange of an atom or group 5 of atoms to create a new compound with similar biological properties to the parent carboxylic acid or ester. The bioisosteric replacement may be physicochemically or topologically based. An example of an isosteric replacement for a carboxylic acid is CONHSO2 (alkyl) such 10 as C0NHS02Me. Compounds of this invention where R2 is CO2H or CH2CO2H, y-ketoacids or 5-ketoacids respectively, may exist in solution as either the open form (a) or the cyclized hemiketal form (b) (y=l for y-ketoacids, y=2 for 15 5-ketoacids). The representation herein of either isomeric form is meant to include the other. o a 20 Likewise it will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms or hydrated forms, all such forms of the compounds being within the scope of the 25 invention. Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical -13- WO 01/90070 PCT/US01/17075 isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds that 5 differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the 10 scope of this invention. that were generically and specifically described in WO 91/15557, WO 99/47154 and WO 00/61542 were tested for activity against caspases in the enzymatic and cell-based 15 assays described below. The new compounds of formula I were found to have unexpectedly better activity relative to the previously described inhibitors. an optionally substituted piperidine ring are represented 20 by formula la below: A number of dipeptidic ICE/caspase inhibitors Compounds of this invention wherein Ring A is la -14- WO 01/90070 PCT/US01/17075 Compounds of this invention wherein Ring A is an optionally substituted tetrahydroquinoline ring are represented by formula lb below: H lb Compounds of this invention wherein Ring A is an optionally substituted tetrahydroisoquinoline ring are represented by formula Ic below: Tf 10 Ic Ring A may be substituted or unsubstituted. Examples of suitable Ring A substituents include one or more groups selected from halogen, -R, -OR, -OH, -SR, 15 protected OH (such as .acyloxy) , phenyl (Ph),"substituted Ph, -OPh, substituted -OPh, -N02, -^CN, -NH2, -NHR, -N (R) 2/ -NHCOR, -NHCONHR, -NHCON(R)2, -NRCOR, -NHC02R, -C02R, -C02H, -COR, -CONHR, -CON (R) 2, -S (0) 2R, -SONH2, -S(0)R, -S02NHR, -NHS(0)2R, =0, =S, =NNHR, =NNR2, =N-OR, =NNHC0R, 20 =NNHC02R, =NNHS02R, or =NR where R is an aliphatic group or a substituted aliphatic group. Preferred compounds of this invention are compounds of formula I that have one or more of the -15- WO 01/90070 PCT/US01/17075 following.features and more preferably all of the following features: (a) R1 is a halomethyl group, more preferably CH2F; 5 (b) R2 is C02H or esters, amides or isosteres thereof; (c) R3 is hydrogen, Ci_6 alkyl, or Ci-6 haloalkyl, more preferably CF3 or C2F5; and (d) Ar is an optionally substituted aryl, more 10 preferably an optionally substituted phenyl. Examples of specific compounds are shown below in Table 1. 15 Table 1 OLx>yO a>h 0 o^N^Y^F. H O Example 1 OI /C02H onr- OJ5 Example 2 ^co,H T ° o'-" "F H II 0 Example 3 -16- WO 01/90070 PCT/US01/17075 cc^ COjH Example 4 Example 5 ^oq,H 0 Example 6 JL /COaH ° °" If T ° Example 7 cr >i' "F o Example 8 Example 9 ri^-N uc°yY rH °«Vr' Example 10 -17- WO 01/90070 PCT/US01/17075 Yy r-cqjH ° Example 11 Br V °0 COgH xCI V ° a ° Example 12 ,CQ,H ° Example 13 .cq,h ° Example 14 ci Example 15 ^ ^co2H o _ N ^rT "F H II 0 Example 16 ■CO„H Example 17 -18- WO 01/90070 PCT/US01/17075 CF. V o CO,H Example 18 V .co2h °0 M lf^F ° Example 21 CI' CI o J XO,H CT N >f F H II ° Example 22 CI /I XO,H CT N >f F H II ° Example 23 Cr° CC^H Example 24 -19-' WO 01/90070 PCT/US01/17075 Example 25 Ck > M02H 0 Example 26 Example 27 > ^CO,H Example 28 V ° a Y Example 30 -20- PCT/US01/17075 o "t -V |sk S vC02H cr y y ° Example 31 / ci .IV S /C02H Example 32 F Example 33 Example 34 CF3/Vf 0 0 Example 35 ° Example 3 6 0 Example 37 -21- WO 01/90070 PCT/USO1/17075 CI- cr c cr V Y T ° Example 38 Example 39 Example 40 Example 41 Y Example 42 Xu/P JUXjY" "AV Y n I C|xyP roo, Example 43 Example 44 -22- WO 01/90070 PCT/USO1/17075 The compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds, as illustrated by the general Scheme I below and by the preparative examples that 5 follow. Scheme I Ar^ ^O. YY R3 O CO2R 10 c,d °<ArJYm o Details: (a) TFA or KOH/MeOH; (b) EDC/DMAP/HOBt; (c) Dess-Martin periodinane; (d) TFA/DCM In Scheme I above, the starting carbamate ester 2 (R is any suitable organic radical) is readily obtained 15 by a carbamoylation reaction between the corresponding alcohol, ArCH(OH)-R3, and the corresponding ester of piperidine-2-carboxylic acid, 1,2,3,4-tetrahydroquinoline-2-carboxylic acid or 1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid. Such 20 carbamate-forming reactions generally use phosgene or an equivalent thereof and are known to those skilled in the -23- WO 01/90070 PCT/US01/17075 art (i.e. formation of an intermediate carbamoyl chloride from the amine, then reaction with the alcohol; or formation of an intermediate chloroformate from the alcohol, then reaction with the amine; or formation of an 5 intermediate chloroformate from the alcohol, then reaction with the amine). Carbamate ester 2 is hydrolyzed using base or, when the ester is a t-butyl group, using trifluoroacetic acid. The acid 3 is then coupled with the amino alcohol 4. Depending on the 10 nature of R1 and R2 an amino ketone may be used, in place of the amino alcohol, which avoids the need for a subsequent oxidation step. In the case of fluoromethyl ketones where R1 is CH2F, the amino alcohol 4 may be obtained according to the method of Revesz. et al., 15 Tetrahedron Lett., 1994, 35, 9693. Finally the hydroxyl in compound 5 is oxidized and the compound treated appropriately according to the nature of R2. For example, if the product I requires R2 to be a carboxylic acid, then R2 in 4 is preferably an ester and the final step in the 20 scheme is acid or base-catalyzed deprotection . The compounds of this invention are designed to inhibit caspases. Therefore, the compounds of this invention may be assayed for their ability to inhibit caspase activity, apoptosis, and the release of IL-lp 25 directly. Assays for each of the activities are known in the art and are described below in detail in the Testing section. According to another embodiment, the invention provides a composition comprising a compound of this 30 invention or a pharmaceutically acceptable salt thereof, as described above, and a pharmaceutically acceptable carrier. -24- WO 01/90070 PCT/US01/17075 If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases. Included among 5 such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, 10 glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 15 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, 20 salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, 25 such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and 30 phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. -25- WO 01/90070 PCT/USO1/17075 The compounds utilized in the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are 5 known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter 10 rate of excretion. Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum, stearate, lecithin, serum proteins, such as human serum albumin, 15 buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium 20 chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, 25 polyethylene glycol and wool fat. ,,v According to a preferred embodiment, the compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being. 30 Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, -26- WO 01/90070 PCT/US01/17075 vaginally or via an implanted reservoir. The term 'parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1, 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used -27- WO 01/90070 PCT/US01/17075 surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for 5 the purposes of formulation. The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In 10 the case of tablets for oral use, carriers that are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried 15 cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. 20 Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room 25 temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols. The pharmaceutical compositions of this 30 invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including -28- WO 01/90070 PCT/US01/17075 diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs. Topical application for the lower intestinal 5 tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used. For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment 10 containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, 15 polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable 20 carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. For ophthalmic use, the pharmaceutical 25 compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic 30 uses, the pharmaceutical compositions may be formulated in an. ointment such as petrolatum. -29- WO 01/90070 PCT/US01/17075 The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical 5 formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents. 10 The above-described compositions are particularly useful in therapeutic applications relating to an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an 15 infectious disease, a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, 20 glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia 25 gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs host disease, organ transplant rejection, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute 30 myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, haemorrhagic shock, sepsis, septic shock, burns, -30- WO 01/90070 PCT/USO1/17075 Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia,epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, 5 congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, 10 spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, or Japanese encephalitis, various forms of liver disease including alcoholic hepatitis, renal disease, polyaptic kidney disease, H. pylori-associated gastric and duodenal ulcer 15 disease, HIV infection, tuberculosis, and meningitis. The compounds and compositions are also useful in treating complications associated with coronary artery bypass grafts and as a component of immunotherapy for the treatment of various forms of cancer. 20 The amount of compound present in the above-described compositions should be sufficient to cause a detectable decrease in the severity of the disease or in caspase activity and/or cell apoptosis, as measured by any of the assays described in the examples. 25 The compounds of this invention are also useful in methods for preserving cells, such as may be needed for an organ transplant or for preserving blood products. Similar uses for caspase inhibitors have been reported (Schierle et al., Nature Medicine, 1999, 5, 97). The 30 method involves treating the cells or tissue to be preserved with a solution comprising the caspase inhibitor. The amount of caspase inhibitor needed will -31- WO 01/90070 PCT/US01/17075 depend on the effectiveness of the inhibitor for the given cell type and the length of time required to preserve the cells from apoptotic cell death. According to another embodiment, the 5 compositions of this invention may further comprise another therapeutic agent. Such agents include, but are not limited to, thrombolytic agents such as tissue plasminogen activator and streptokinase. When a second agent is used, the second agent may be administered 10 either as a separate dosage form or as part of a single dosage form with the compounds or compositions of this invention. It should also be understood that a specific dosage and treatment regimen for any particular patient 15 will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity 20 of the particular disease being treated. The amount of active ingredients will also depend upon the particular compound and other therapeutic agent, if present, in the composition. In a preferred embodiment, the invention 25 provides a method of treating a mammal, having one of the aforementioned diseases, comprising the step of administering to said mammal a.pharmaceutically acceptable composition described above. In this embodiment, if the patient is also administered another 30 therapeutic agent or caspase inhibitor, it may be delivered together with the compound of this invention in a single dosage form, or, as a separate dosage form. -32- WO 01/90070 PCT/USO1/17075 When administered as a separate dosage form, the other caspase inhibitor or agent may be administered prior to, at the same time as, or following administration of a pharmaceutically acceptable composition comprising a 5 compound of this invention. In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed 10 as limiting the scope of the invention in any way. Synthetic Examples [3S/R, (2S)]-3-(l-Benzyloxycarbonyl-2-15 piperidinecarboxamido)-5~fluoro-4-oxo-pentanoic acid (Example 1) XG,H iTt"f 20 Method A: (S) -Piperidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester ■*OMe To a stirred suspension of (S)-piperidine-2-carboxylic 25 acid methyl ester hydrochloride salt (5.0g, 27. 8mmol) in dichloromethane (DCM) (35mL) at 0°C was added diisopropylethylamine (DIPEA) (lO.lmL, 58.4mmol) followed -33- WO 01/90070 PCT/US01/17075 by N-(benzyloxycarbonyloxy)succinimide (7.63g, 30.6mmol). The reaction mixture was allowed to warm to room temperature and stirred overnight. The residue was diluted with DCM and washed with 1.0-M HC1. The organic 5 layer was washed with brine, dried (Na2S04)", filtered and concentrated in vacuo. The residue was purified by flash chromatography (20% ethyl acetate in hexane) to afford the title compound as a pale yellow oil (7.72, 100%): 1H NMR (400MHz, CD3OD) 6 1.19-1.88 (5H, m) , 2.15-2.28 (1H, 10 m) , 2.91-3.12 (1H, m) , 3.70-3.73 (3H, 2s), 4.00-4.07 (1H, m), 4.82-4.87 (1H, m) , 5.03-5.21 (2H, m), 7.24-7.39 (5H, m) ; 13C NMR (100MHz, CD3OD) 5 22.0, 22.1 (CH2) , 26.0, 26.1 (CH2) , 28.1 (CH2) , 43.4, 43.5 (CH2) , 53.1 (CH3) , 56.2, 56.5 (CH), 68.8, 68.9 (CH2) , 129.2 (CH), 129.5 (CH), 129.9 15 (CH), 138.4 (C), 167.0 (CO), 173.7 (CO). Method B: (S)-Piperidine-1,2-dicarboxylic acid 1-benzyl ester 20 To a stirred solution of (S)-piperidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (8.0g, 28.8mmol) in MeOH (75mL) and water (38mL) at . 0°C was added powdered KOH (1.78g, 31.7mmol). The reaction mixture was allowed to stir for 16h at room temperature and then the MeOH was 25 removed in vacuo. The residue was diluted with water and washed DCM. The aqueous layer was acidified with 1.0-M HC1 and extracted with ethyl acetate three times. The combined organic extracts were dried (Na2SO,j), filtered and concentrated in vacuo to afford the title compound as 34 WO 01/90070 PCT/US01/17075 pale yellow oil (7.6 g, 100%): 1H NMR (400MHz, CD3OD) 6 1.36-1.61 (2H, m), 1.70-1.85 (3H, m), 2.28-2.40 (1H, m) , 3.05-3.26 (1H, m) , 4.06-4.14 (1H, m) , 4.89-5.26 (4H, m) , 7.37-7.48 (5H, m) ; 13C NMR (100MHz, CD3OD) □ 20.5, 20.6 5 (CH2) 24.6, 24.7 (CH2) , 26.6 (CHZ) , 41.8, 41.9 (CH2) , 54.5, 54.7 (CH) , 67.2, 67.3 (CH2) / 127.6 (CH) , 127.9 (CH) , 128.4 (CH), 136.9 (C), 173.4 (CO). Method C: 10 [3S/R, (2S) ] -3-(l-Benzyloxycarbonyl-2- piperidinecarboxamido)-5-fluoro-4-hydroxy-pentanoic acid tert-butyl ester A stirred mixture of (S)-piperidine-1,2-dicarboxylic 15 acid 1-benzyl ester (606mg, 2.30mmol), 3-amino-5-fluoro-4-hydroxy-pentanoic acid tert-butyl ester (500mg, 2.42mmol), HOBT (344mg, 2.53mmol), DMAP (323mg, 2.65mmol) and anhydrous THF (17mL) was cooled to 0°C then EDC (485mg, 2.53mmol) was added. The mixture was allowed to 20 warm to room temperature during 16h then concentrated under reduced pressure. The residue purified by flash chromatography (5% ethyl acetate in petroleum spirit -50% ethyl acetate in petroleum spirit) to give the title compound as a colourless oil (871mg, 84%) : 1H NMR (400MHz, 25 CDCI3) 5 1.44 (9H, s), 1.50-3.09 (9H, m) , 3.87-5.18 (9H, m) , 6.72-7.04 (1H, m) , 7.22-7.37 (5H, m) ; 19F NMR (376MHz, CDCI3) 5 -229.1, -229.3, -230.0, -230.3, -230.5. F OH -35- WO 01/90070 PCT/US01/17075 Method D: [3S/R, (2S)]-3- (l-Benzyloxycarbonyl-2-piperidinecarboxamido)-5-fluoro-4-oxo-pentanoic acid tert-butyl ester <7 ^CO.tB u X02IBi 0°Vir F O A stirred solution of [3S/R, (2S)]-3-(l-benzyloxycarbonyl-2-piperidinecarboxamido)-5-fluoro-4-10 hydroxy-pentanoic acid tert-butyl ester (871mg, 1.93mmol) in anhydrous dichloromethane (DCM) (40mL) was treated at 0°C with 1,1,1 triacetoxy-1,1-dihydro-l,2-beziodoxol-3(li?)-one (980mg, 2.31mmol). The mixture was stirred at room temperature for 16h, diluted with ethyl acetate and 15 washed with a 1:1 mixture of aqueous NaHS04 and aqueous Na2S203. The organic layer was collected, dried (MgSO^) and concentrated. The residue was purified by flash chromatography (40% ethyl acetate in hexane) to.give the title compound as a colourless oil (738mg, 85%): 1H NMR 20 (400 MHz, CDCI3) 6 1.46 (9H, s) , 1.39-1.74 (5H, m) , 2.25-2.36 (1H, m) , 2.70-3.06 (3H, m), 4.09-4.12 (1H, m) , 4.80-5.19 (6H, m) , 7.01-7.15 (1H, m), 7.28-7.37 (5H, m) ; 13C NMR (100MHz, CDCI3) 8 20.7 (CH2) , 25.1/26.0 (CH2) , 28.3 (CH3) , 36.6, 36.7 (CH2) , 42.5, 42.7 (CH2) , 52.8 (CH) , 55.2 25 (CH), 68.1, , 68.2 (CH2) , 82.7 (C) , 84.5, 84.6 (CH2F) , 128.3 (CH), 128.6 (CH), 129.0 (CH), 136.7 (C), 170.3, 170.4 (CO), 171.5 (CO), 202.0 (CO) ; 19F NMR (376MHz, CDCI3) 8 -231.6, -231.9, -232.2. -36- WO 01/90070 PCT/USOl/17075 Method E: [3S/R, (2S)]-3-(l-Benzyloxycarbonyl-2-' piperidinecarboxamido)-5-fluoro-4-oxo-pentanoic acid 5 (Example 1) Trifluoroacetic acid (TFA) (12mL) was added to a stirred ice cold solution of [3S/R, (2S)]-3-(1-benzyloxycarbonyl-10 2-piperidinecarboxamido)-5-fluoro-4-oxo-pentanoic acid tert-butyl ester (698mg, 1.55mmol) in anhydrous DCM (38mL). The mixture was stirred at 0°C for 0.5h then at room temperature for 0.5h. The mixture was concentrated under reduced pressure and then the residue was dissolved 15 in dry DCM. This process was repeated several times in order to remove excess TFA. The gum was lyophilized twice from HPLC grade water / acetonitrile to afford the title compound as a white solid foam (481mg, 79%): IR (solid) 1736, 1665, 1517, 1436, 1255, 1174, 1041, 931cm"1; 20 1H NMR (400MHz, d6-DMSO) 5 1.12-1.40 (2H, m) , 1.45-1.68 (3H, m) , 2.05 (1H, m) , 2.61-2.63 (1H, m) , 2.70-2.87 (1H, m), 2.98-3.21 (1H, m) , 3.91 (1H, m) , 4.28-4.75 (3H, m), 4.91-5.30 (3H, m), 7.25-7.42 (5H, m) , 7.80-8.59 (1H, brm) , 12.5 (1H, brs) ; 13C NMR (100MHz, d6-DMSO) 8 (DMSO) 25 20.0 (CH2), 24.6 (CH2) , 27.3 (CH2) , 34.7 (CH2) , 42.1 (CH2) , 52.1, 52.4 (CH) , 54.5 (CH) , 66.7 (CH2) , 84.2 (CH2F) , 127.8 (ArCH), 128.1 (ArCH), 128.7 (ArCH), 131.1 (ArC), 171.4 (CO), 172.0 (CO), 172.1 (CO), 202.8 (CO); 19F NMR (376MHz, -37- WO 01/90070 PCT/USO1/17075 de-DMSO) 5 -226.6, -226.8, -226.9, -232.4, -232.6, -232.7; MS (FAB +ve, HR) Calculated for Ci9H24FN206 (MH+) 395.1618, found 395.1625. 5 [3S/R, (2S)]-3- (1- (2-Chlorobenzyloxycarbonyl) -2- piperidinecarboxamido)-5-fluoro-4-oxo-pentanoic acid (Example 2)' 1° Method F: (S) -1-(2-Chlorobenzyloxycarbonyl)-piperidine-2-carboxylic acid methyl ester 15 To a vigorously stirred solution of (S)- pipecolic acid methyl ester hydrochloride (500mg, 2.79mmol) in dry DCM (lOmL) cooled in an ice-bath, was added dropwise Et3N (705mg, 6.96itimol) followed by 2- chlorobenzyl chloroformate (made from 2-chlorobenzyl 20 alcohol using the method described in J. Med. Chem. r 1998, 41, 1315-1343) (857mg, 4.18mmol). The resulting suspension was stirred at 0°C for a further 0.75h, diluted with ethyl acetate (30mL) and poured into 1.0-M HCl (30mL). The organic layer was separated and washed 25 sequentially with 1.0-M HCl (20mL), aq.NaHC03 (20mL) and brine (20mL). The organic layer was then dried (NaS04), -38- WO 01/90070 PCT/USO1/17075 filtered and concentrated under reduced pressure to give a colourless oil. The oil was purified by column chromatography (15% ethyl acetate in hexane) to give the title compound as a colorless viscous oil (824mg, 95%): 1H 5 NMR (400MHz, CDC13) 1.2-1.4 (1H, m) , 1.4-1.6 (1H, m) , 1.6-1.8 (3H, m) , 2.2-2.3 (1H, m), 2.9-3.2 (1H, m), 3.7-3.8 (3H, m) , 4.0-4.2 (1H, m) , 4.8-5.0 (1H, m) , 5.2-5.4 (2H, m) , 7.2-7.3 (2H, m) , 7.3-7.5 (2H, m) 10 [3S/R, (2S)]-3- (1-(2-Chlorobenzyloxycarbonyl)-2- piperidinecarboxamido)-5-fluoro-4-oxo-pentanoic acid (Example 2) 15 This was prepared from (S)-1-(2-chlorobenzyloxycarbonyl)- piperidine-2-carboxylic acid methyl ester using procedures similar to those described above in Methods.B- E (161mg, 70% last step) : IR (solid) 1668, 1789 cm-1; 1H 20 NMR (400MHz, d6-DMS0) 8 1.1-1. 8 (5H, m) , 2.0-2.2 (1H, m) , 2.4-2.9 (2H, m) , 3.0-3.5 (1H, m) , 3.8-4.0 (1H, m), 4.2- 4.8 (3H, m), 5.0-5.4 (3H, m), 7.3-7.6 (4H, m), 7.8-8.7 (1H, m) , 12.0-13.0 (1H, br s) ; 13C NMR (100MHz, ds-DMSO) 8 20.50, 20.77, 25.01, 25.14, 27.80, 28.18 (CH2) , 33.40, 25 35.20 (CH2) , 42.71 (CH2) , 47.89, 48.05, 52.65, 52.91, 53.35, 54.82, 55.05 (2 x CH), 64.66, 64.77 (CH2) , 81.94, 82.04, 83.70, 83.80, 85.60 (CH2) , 128.21, 130.11, 130.18, 130.40, 130.61 (ArCH), 133.08, 134.93, 134.95 (ArC), -39- WO 01/90070 PCT/US01/17075 155.72, 156.40, 171.72, 172.20, 172.39, 172.58, 172.65, 173.83, 203.14, 203.29 (CO) ; 19F NMR (376MHz, d6~DMSO) 5 -226.6, -226.8, -226.9, -230.2, -230.4, -232.4, -232.6, -232.6; Low Res MS ES+ 429.4, ES- 427.5. [3S/R, (2S)]-3- (1-Benzyloxycarbonyl-l,2,3,4-tetrahydro-gulnolinyl-2-carboxamido)-5-fluoro-4-oxo-pentanoic acid (Example 3) This was prepared from (S)-1-benzyloxycarbonyl-l, 2, 3, 4-tetrahydro-quinoline-2-carboxylic acid (US 4,461,896) using procedures similar to those described above in Methods C-E (142mg, 100%): IR (solid) 2981, 1684, 1653, 15 1522, 1492, 1394, 1323, 1207, 1053, 1018; XH NMR (400MHz, de-DMSO) 8 1.71 (1H, m) , 2.29 (1H, m), 2.31-2.88 (4H, m) , 4.00-5.30 (6H, m), 6.97 (1H, m), 7.12 (2H, m), 7.38 (5H, m) , 7.69 (1H, m), 8.25+8. 62+8.72 (1H, 3xm); 13C NMR (100MHz, d6-DMSO) 5 26.07, 26.20 (CH2) , 28.52, 28.76, 20 28.95 (CH2), 35.13, 35.34 (CH2) , 52.54, 52.84, 53.21 (CH) , " 58.31, 58.35 (CH), 84.73 (FCH2, J 177Hz), 124.34, 126.96, 128.27, 128.39, 128.45, 128.49, 128.55, 128.78, 128.83 (CH), 132.19, 12.41 (C), 137.04, 137.78 (C=0), 154.98 (C=0), 172.66, 172.73 (C=0), 203.00, 203.15, 203.29 25 (FCH2C=0) ; 13F NMR (376MHz, ds-DMSO) 8 -226.59 (t, J 45Hz) , -226.91 (t, J 45Hz), -232.76 (t, J 45Hz). 5 10 o -40- WO 01/90070 PCT/USO1/17075 [3S/R, (2S)3-5-Fluoro-4-oxo-3- (1- (2-trifluoromethyl benzyloxycarbonyl) -2-piperidinecarboxamido) -pentanoic acid (Example 4) This was prepared from 2-trifluoromethylbenzyl alcohol using procedures similar to those described above in Methods F, and B-E to give an off-white solid (150mg, 79% last step): IR (solid) 1672, 1737, 17867 cm"1; JH KMR 10 (400MHz, de-DMSO) 5 1.1-1.4 (2H, m) , 1.5-1.7 (3H, m) , 2.0-2.2 (1H, m), 2.5-2.6 (1H, m) , 2.7-3.0 (1H, m), 3.0-3.4 (1H, m), 3.9-4.0 (1H, m) , 4.3-4.8 (2.7H, m), 5.0-5.4 (3.3H, m), 7.5-7.9 (4H, m) , 7.9-8.6 (1H, m); 13C NMR (100MHz, de-DMSO) 5 19.98, 20.23, 24.50, 27.27, 27.62 15 (CH2), 32.96, 34.65 (CH2) , 42.12 (CH2) , 47.45, 47. 60, 52.15, 52.41, 52.89, 54.52 (2x CH) , 63.11, 63.38 (CH2) , 81.48, 81.57, 83.32, 85.05(CH2F)f 120.53, 123.35, 125.97 (ArC), 126.35, 128.94, 130.13, 133.18 (ArCH), 135.07 (ArC), 171.56, 172.02, 172.07, 173.26, 174.14, 202.70 20 (CO) ; 19F NMR (376MHz, ds-DMSO) 5 -59.3, -226.7, -226.7, -226.8, -226.9, -230.2, -230.5, -232.5, -232.6, -232.7, -232.7. -41- WO 01/90070 PCT/US01/17075 [3S/R, (2S)]-3-(1-(3-Chlorobenzyloxycarbonyl) -2-piperidinecarboxamido) -5-fluoro-4-oxo-pentanoic acid (Example 5) This was prepared from 3-chlorobenzyl alcohol using procedures similar to those described above in Methods F, and B-E to give an off-white solid (99mg, 54% last step): 10 IR (solid) 1672, 1788 cm"1; *H NMR (400MHz, ds-DMSO) 5 1.1-1.4 (2H, m), 1.5-1.7 (3H, m) , 2.0-2.2 (1H, m), 2.4-2.6 (1H, m) / 2.6-2.9 (1H, m) , 3.0-3.3 (1H, m), 3.8-4.0 (1H, m.) , 4.2-4.8 (2.7H, m) , 5.0-5.3 (3.3H, m) , 7.2-7.5 (4H, m), 7.5-8.7 (1H, m) ; 13C NMR (100MHz, d6-DMS0) 8 19.99, 15 20.24, 24.57, 27.09, 27.27, 27.63 (CH2) , 32.96, 34.72, 52.87, 54.53 (2x CH) , 65.79 (CH2) , 81.51, 81.56, 83.28, 85.06 (CH2F), 126.99, 127.50, 128.05, 130.65 (ArCH), 133.40, 139.72, 139.75 (ArC), 171.26, 171.80, 172.03, 20 172.08, 173.27, 174.14, 202.58, 202.72 (CO); 19F NMR (376MHz, de-DMSO) 5 -226. 6, -226.8, -226.9, -230.2, -230.3, -232.4, -232.5, -232.6. 5 CI O 34.86 (CH2), 42.14 (CH2) , 47.45, 47.61, 52.20, 52.40 -42- WO 01/90070 PCT/USOl/17075 [3S/R, (2S)]-5-Fluoro-4-oxo~3-(1-(3-trifluoromethyl benzyloxycarbonyl)-2-piperidinecarboxamido)-pentanoic acid (Example 6) o This was prepared from 3-trifluoromethylbenzyl alcohol using procedures similar to those described above in Methods F, and B-E to give an off-white solid (142mg, 64% 10 last step): IR (solid) 1670, 1788 cm-1; 1H NMR (400MHz, d6-DMS0) 5 1.1-1.7 (5H, m) , 2.0-2.2 (1H, m) , 2.5-2.9 (2H, m) , 3.0-3.3 (1H, m) , 3.8-4.0 (1H, m) , 4.2-4.8 (3H, m) , 4.9-5.3 (3H, m) , 7.5-7.8 (4H, m) , 7.8-8.6 (1H, m) ; 13C NMR (100MHz, d6-DMSO) 6 20.02, 20.28, 24.63, 27.10, 27.28, 15 27.66 (CH2), 32.86, 34.69 (CH2) , 42.19 (CH2) , 47 .40, 47.57, 52.19, 52.40, 54.58 (2x CH) , 65.29, 65.89 (CH2Ar) , 83.30, 85.02 (CH2F), 124.20, 124.89, 129.91, 131.80 (4x ArCH), 138.71, 138.74 (2x ArC), 171.91, 172.09, 172.13, 173.33 (CO) ; 1SF NMR (376MHz, d6-DMSO) 8 -61.5, -226.7, -20 226.9, -226.9, -230.2, -230.4, -232.5, -232.6, -232.7; Low Res MS ES+ 4 61.3, ES- 4 63.2. -43- WO 01/90070 PCT/US01/17075 5 [3S/R, (2S) ] -3- (1- (3, 4-Dichlorobenzyloxycarbonyl) -2-piperidinecarboxamido)-5-fluoro-4-oxo-pentanoic acid (Example 7) a ? O rJ^K CQjH 9 o This was prepared from 3,4-dichlorobenzyl alcohol using procedures similar to those described above in Methods F, and B-E to give an off-white solid (167mg, 70% last 10 step) : IR (solid) 1671, 1785 cm"1; XE NMR (400MHz, cfe-DMSO) 8 1.1-1.8 (5H, m), 2.0-2.2 (1H, m), 2.5-2.9 (2H, m) , 3.0-3.3 (1H, m) , 3.8-4.0 (1H, m) , 4.2-4.8 (2.5H, m), 5.0-5.4 (3.5H, m) , 7.2-7.4 (1H, m) , 7.5-7.7 (2H, m) , 7.7-8.6 (1H, m) ; 13C NMR (100MHz, ds-DMSO) 8 19.99, 24.45, 24.61, 15 27.26, 27.61 (3x CH2) , 32.88, 34.68 (CH2) , 42.71 (CH2) , 47.42, 47.57, 52.20, 52.40, 54.52 (2x CH), 65.12, 65.27 (CH2Ar), 81.53, 83.30, 85.08 (CH2F) , 127.87, 128.03, 129.59, 129.76 (ArCH), 130.64 (ArC), 131.01 (ArCH), 131.37, 138.39, 138.42 (ArC), 171.88, 172.07, 172.12, 20 173.32, 202.78 (CO) ; 13F NMR (376MHz, d6-DMSO) 5 -226.6, -226.8, -226.9, -230.2, -230.3, -232.4, -232.6, -232.6. -44- WO 01/90070 PCT/USO1/17075 [3S/R, (2S) 3-5-Fluoro-3-(1-(3-methoxybenzyloxycarbonyl)-2-piperidinecarboxamido) -4-oxo-pentarLoic acid (Example 8) ?Me V—iT~Y 5 ° This was prepared from 3-methoxybenzyl alcohol using procedures similar to those described above in Methods F, and B-E to give an off-white solid (112mg, 58% last step) : IR (solid) 1670, 1738, 1785 cm"1; XH NMR (400MHz, 10 d6-DMSO) 5 1.1-1.7 (5H, m) , 2.0-2.2 (1H, m) , 2.5-3.0 (2H, m), 3.0-3.3 (1H, m), 3.8 (3H, s) , 3.8-4.0 (1H, m), 4.3-4.8 (2.5H, m) , 5.0-5.4 (3.5H, m) , 6.8-7.0 (3H, m) , 7.2-7.3 (1H, m) , 7.7-8.6 (1H, m) ; 13C NMR (100MHz, d6-DMSO) 6 20.01, 20.29, 24.51, 24.64, 27.31 (3x CH2), 32.89, 34.64, 15 34.71 (CH2) , 42.14 (CH2), 47.40, 52.17, 52.37, 54.50 (2x CH), 55.36 (OCH3) , 66.51 (CH2Ar) , 81.42, 81.52, 83.28, 85.09 (CH2F), 113.15, 113.51, 119.61, 119.74, 129.88 (ArCH), 138.71, 138.78, 156.71, 159.62 (ArC), 171.96, 172.08, 172.14, 173.33, 202.65, 202.80 (CO); 19F NMR 20 (376MHz, d6-DMSO) 8 -226.7, -226.8, -226.9, -230.2, -230.4, -230.4, -232.4, -232.6, -232.6. -45- WO 01/90070 PCT/USO1/17075 [3S/R, (2S, cx-R) ]-5-Fluoro-3- (1- (g-trifluoromethyl benzyloxycarbonyl)-2-piperidinecarboxamido)-4-oxo-pentanoic acid (Example 9) F 5 o This was prepared from (R) -(-)'-a- (trifluoromethyl) -benzyl alcohol using procedures similar to those described above in Methods F, and B-E to give an off-white solid (llmg, 54% last step): NMR (400MHz, d6-DMSO) 6 1.1-1.8 (5H, 10 m) , 1.9-2.2 (1H, m) , 2.3-3.0 (2H, m) , 3.0-3.5 (1H, m) , 3.8-4.2 (1H, m) , 4.3-4.9 (2.5H, m) , 5.0-5.3 (1.5H, m), 6.2-6.4 (1H, m), 7.4-7.6 (5H, m),'7.8-8.7 (1H, m) ; 19F NMR (376MHz, ds-DMSO) 5 -75.7, -232.1, -232.5, -232.6, -232.7. 15 [3S/R, (2S)]-5-Fluoro-4-oxo-3-(1-(2- pyridinyliaethoxycarbonyl) -2-piperidinecarboxamido) -pentanoic acid (Example 10) o -46- WO 01/90070 PCT/USO1/17075 Method G: (S) -1- (2-Pyridinylmethoxycarbonyl) -piperidine-2-carboxylic acid methyl ester °Y O o OMe To a solution of 2-pyridylcarbinol (209p.L, 2.17mmol) and dry THF (lOmL) at 0°C under an atmosphere of nitrogen was added NaH (60% dispersion in mineral oil, 87mg, 2.17mmol), and the reaction mixture was stirred at 0°C for 30 mins. This mixture was then added dropwise to a solution of (S)-1-(chlorocarbonyl)-2-piperidinecarboxylic acid methyl ester (EP 75737) (425mg, 2.06mmol) and dry THF (lOmL) at 0°C. The reaction mixture was allowed to stir for 1.5 h while warming to room temperature, then poured onto aq.KHS03 (25mL) and extracted with EtOAc (2 x 50mL). The combined organic phases were washed with aq.NaHC03, followed by brine, dried (MgS04) , filtered and concentrated in vacuo. The residue was purified by column chromatography (30% ethyl acetate in hexane) to give the title compound as a colourless oil (340mg, 59%): 1H NMR (400MHz, CDC13) 8 1.3-1.8 (5H, m) , 2.3 (1H, bs) , 3.0 (0.5H, t, J 12.0Hz), 3.1 (0.5H, t, J12.0Hz), 3.9 (3H, s), 4.2 (1H, m), 5.0 (1H, m), 5.3 (2H, dd, J 14.0Hz), 7.2-7.4 (2H, m) , 7.7 (1H, m), 8.6 (1H, m) -47- WO 01/90070 PCT/USO1/17075 [3S/R, (2S) ]-5-Fluoro-4-oxo-3-(1-(2-pyridinylmethoxycarbonyl) -2-piperidinecarboxainido) -pentanoic acid (Example 10) 5 This was prepared from (S)-l-(2- pyridinylmethoxycarbonyl) -piperidine-2-carboxylic acid 10 methyl ester using procedures similar to those described above in Methods B-E to give a clear glass (67mg, 100% last step): """H NMR (400MHz, d6~DMS0) 6 1.23-1.61 (5H, m) , 2.59 (1H, m) , 2.82 (1H, m), 3.21 (1H, m), 3.95 (1H, m) , 4.29-4.75 (3H, m) , 5.09-5.21 (4H, m), -7.45-7.52 (2H, m), 15 7.94-8.59 (3H, m) , 12.5 (1H, bs) ; 13C NMR (100MHz, d6- DMSO) 5 18.48 (CH2) , 22.97 (CH2) , 23.13 (CH2) , 25.73 (CH2) , 33.15 (CH2), 40.74 (CH2) , 50.67, 50.94 (CH), 53.08 (CH), 64.85, 65.10 (CH2) , 81.85 (d, J 178Hz, CH2F), 120.63 (CH) , 122.27 (CH), 137.55 (CH), 146.61 (CH),154.34"(C), 20 156.92, 157.28 (C) , 170.56, 170.63 (C), 171.81 (C), 201.25 (CO); 19F NMR (376MHz, d6-DMSO) 8 -75.21, -226.66, -226.70, -226.83, -226.87, -230.37, -232.38, -232.57, -232.62, -232.64. -48- WO 01/90070 PCT/US01/17075 [3S/R, (25)]-5-Fluoro-4-oxo-3-(l-(3-thienylmethoxycarbonyl) -2-piperidinecarboxamido) -pentanoic acid (Example 11) 5 This was prepared from 3-thiophenemethanol using procedures similar to those described above in Methods G, and B-E to give a white solid (27mg, 39% last step) after 10 preparative HPLC: IR (solid) 3339, 2952, 1786, 1735, 1663cm"1; XH NMR (400MHz, d6-DMSO) 5 1.22-1.32 (2H, m) , 1.41-1.57 (3H, m), 2.67 (1H, m), 2.71 (1H, m), 3.08 (1H, m) , 3.87 (1H, m), 4.64-5.53 (5H, m), 7.08 (1H, m), 7.45-7.52 (2H, m) , 8.44 (1H, m) , 12.50 (1H, bs) ; 13C NMR 15 (100MHz, ds-DMSO) 5 18.48, 18.58 (CH2) , 23.11 (CH2) , 25. 87-(CH2) , 38.98 (CH2) , 52.71 (CH) , 52.94 (CH) , 60.87, 60.90 (CH2), 122.22 (CH), 122.73 (CH), 126.07, 126.32 (CH), 136.50 (C), 170.23 (CO); No signal seen for AspCH2, CH2F or ketone CO, due to broadening of the signals; 19F NMR 20 (376MHz, d6-DMSO) 5 -226.62, -226.85, -226.90, -230.28, -232.37, -232.58, -232.69. -49- WO 01/90070 PCT/USO1/17075 [3S/R, (2S) ]-3- (1- (3-Bromobenzyloxycarbonyl) -2-piperidinecarboxamido)-5-fluoro-4-oxo-pentanoic acid (Example 12) 5 O This was prepared from 3-bromobenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a white solid (119mg, 58% last step): IR (solid) 1670, 1738, 1785cm-1; aH NMR (400MHz, d6~DMS0) 10 51.1-1.7 (5H, m) , 2.0-2.2 (1H, m) , 2.4-2.9 (2H, m), 2.9-3.3 (1H, m) , 3.8-4.0 (1H, m), 4.2-4.8 (2.6H, m), 5.0-5.4 (3.4H, m) , 7.2-7.4 (2H, m), 7.4-7.6 (2H, m), 7.7-8.7 (1H, m) ; 13C NMR (100MHz, ds-DMSO) 5 19.98, 20.26, 24.61, 27.09, 27.29, 27.66 (CH2) , 32.90, 34.71 (CH2) , 42.17 15 (CH2) , 47 .40, 47.57, 52.19, 52.38, 54.32, 54.52 (2x CH) , 65.80 (CH2Ar), 81.54, 83.30, 85.10 (CH2F), 121.96 (ArC), 126.54, 126.76, 130.28, 130.44, 130.98 (ArCH), 139.97, 140.00 (ArC), 156.05, 171.75, 172.08, 173.32, 202.78 (Cp) ; 19F NMR (376MHz, d6-DMSO) 5 -226.6, -226.8, -226.9, -20 230.1, -230.2, -230.3, -232.4, -232.5, -232.5, -232.6. -50- WO 01/90070 PCT/US01/17075 [3S/R, (2S)]-3- (1-(2, 4-Dichlorobenzyloxycarbonyl) -2-piperidinecarboxamido) -5-fluoro-4-oxo-pentanoic acid (Example 13) 5 This was prepared from 2,4-dichlorobenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a white solid (80mg, 64% last step): IR 10 (solid) 1671, 1739, 1782cm"1; NMR (400MHz, d6-DMSO) 5 1.1-1.8 (5H, m) , 2.0-2.2 (1H, m) , 2.5-2.9 (2H, m), 3.0-3.3 (1H, m), 3.8-4.0 (1H, m), 4.2-4.8 (2.6H, m), 5.0-5.4 (3.4H, m) , 7.4-7.6 (2H, m), 7.6-7.7 (1H, m), 7.7-8.6 (1H, m) ; 13C NMR (100MHz, d6-DMSO) 6 22.45, 26.96, 27.10, 15 29.75, 30.12 (CH2) , 35.39, 37.15 (CH2) , 44.70 (CH2) , 49.89, 50.07, 54.63, 54.89, 57.03 (2x CH),.66.10, 66.24 (CH2Ar), 84.02, 85.62, 87.61 (CH2F) , 130.35, 131.71, 133.77 (ArCH), 136.15, 136.18, 136.26 (ArC), 174.07, 174.14, 174.34, 174.56, 174.62, 175.81, 205.13 (CO); 19F 20 NMR (376MHz, d6-DMSO) 8 -226.7, -226.8, -226.9, -227.2, -230.2, -230.3, -230.4, -232.4, -232.6, -232.6, -232.6. -51- WO 01/90070 PCT/US01/17075 [3S/R, (25)]-3-(1-(3, 5-Dichlorobenzyloxycarbonyl)-2-piperid.inecarboxam.ido) -5-fluoro-4-oxo-pentanoic acid (Example 14) CI F O 20 This was prepared from 3,5-dichlorobenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a white solid (95mg, 52% last step): IR (solid) 1670, 1737, 1783cm"1; 1H NMR (400MHz, cfe-DMSO) 8 1.1-1.8 (5H, m) , 2.0-2.2 (1H, m) , 2.4-2.9 (2H, m) , 3.0-3.3 (1H, m), 3.8-4.0 (1H, m) , 4.3-4.8 (2.6H, m), 4.9-5.4 (3.4H, m), 7.3-7.5 (2H, m),- 7.5-7.6 (1H, m) , 7.7-8.6 (1H, m) ; 13C NMR (100MHz, ds-DMSO) 8; 1SF NMR (376MHz, cfe-DMSO) 8 -226.6, -226.8, -226.9, -230.0, -230.2, -230.2, -230.2, -232.5, -232.5, -232.5, -232.6. [3S/R, (2S)]-3-(1-(2, 4-Bis(trifluoromethyl)benzyloxycarbonyl)-2-piperidinecarboxamido) -5-fluoro-4-oxo-pentanoic acid (Example 15) This was prepared from 2,4-bis(trifluoromethyl)benzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a white solid (59mg, 4 9% last step) : IR (solid) 1655, 1684, 1735, 1772cm"1; XH NMR o -52- WO 01/90070 PCT/USO1/17075 (400MHz, de-DMSO) 8 1.1-1.8 (5H, m) , 2.0-2.2 (1H, m) , 2.5-3.0 (2H, m), 3.0-3.3 (1H, m) , 3.8-4.0 (1H, m), 4.2-4.8 (2.7H, m) , 5.0-5.5 (3.3H, m) , 7.7-8.0 (2H, m), 8.0-8.2 (1H, m), 8.2-8.6 (1H, m) ; 13C NMR (100MHz, d6-DMSO) 8; 19F 5 NMR (376MHz, de-DMSO) 8 -59.88, -59.91, -61.80, -61.81, -61.84, -226.7, -226.8, -226.8, -226.9, -230.2, -230.5, -232.5, -232.7, -232.7, -232.7. [3S/R, (2S)]-3-(1-(4-Chlorobenzyloxycarbonyl)-1,2,3,4-10 tetrahydro-quin.ollnyl-2-carboxairildo) -5-fluoro-4-oxo-pentanoic acid (Example 16) This was prepared from 4-chlorobenzyl alcohol and (S)—1 — 15 (chlorocarbonyl)-1,2,3, 4-tetrahydro-quinoline-2- carboxylic acid methyl ester [prepared using a procedure similar to the one described for the synthesis of (S)—1 — (chlorocarbonyl)-2-piperidinecarboxylic acid methyl ester in EP 75737] using procedures similar to those described 20 in Methods G, and B-E to produce, after reverse phase HPLC, a white solid (57.4mg, 21%): IR (solid) 1794, 1694, 1522, 1384, 1317, 1203, 1045cm"1; 1H NMR (400MHz, d6-DMSO) 8 1.59-1.78 (1H, m), 2.20-2.40 (1H, m), 2.40-2.82 (4H, m), 4.10-5.28 (6H, m) , 6.90-7.20 (3H, m), 7.31-7.48 (4H, 25 m), 7.60-7.77 (1H, m) , 8.20-8.70 (1H, m) ; 13C NMR (100MHz, de-DMSO) 8 25.53, 28.01, 34.80, 52.03, 57.85, 66.63, 83.12, 84.90, 126.41, 126.45, 127.86, 128.77, 129.85,. o -53- WO 01/90070 PCT/US01/17075 129.93, 132.93, 135.58, 137.22 172.01, 172.07, 172.20, 202.63, 202.77; 1SF NMR (376MHz, d6-DMSO) 8 -226.66, -226.93, -232.77 (bm) , -232.91 (bm); Low Res MS ES+ 477.131, ES- 475.20. [3S/R, (2S)]-3-(1-(3,4-Dichlorobenzyloxycarbonyl)-1,2,3, 4-tetrahydro-quinolinyl-2-carboxamldo)-5-fluoro-4-oxo-pentanolc acid (Example 17) This was prepared from 3,4-dichlorobenzyl alcohol and (S)-1-(chlorocarbonyl)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid methyl ester [prepared using a procedure similar to the one described for the synthesis of (S)-l-15 (chlorocarbonyl)-2-piperidinecarboxylic acid methyl ester described in EP 75737] using procedures similar to those described in Methods G, and B-E to produce, after reverse phase HPLC, a white solid (131.5mg, 35%): IR (solid) 1693, 1527, 1374, 1331, 1198, 1055, 1026cm"1; ^ NMR 20 (400MHz, de-DMSO) 8 1.58-1.79 (1H, m) , 2.19-2.39 (1H, m) , 2.40-2.83 (4H, m), 4.00-5.25 (6H, m) , 6.92-7.02 (1H, m), 7.05-7.21 (2H, m) , 7.30-7.40 (1H, m) , 7.55-7.78 (3H, m), 8.21-8.75 (1H, m) ; 13CNMR (100MHz, ds-DMSO) 8 24.11, 24.21, 26.58, 26.78, 26.96, 31.68, 33.18, 33.37, 50.63, 50.92, 25 56.41, 56.49, 56.74, 64.30, 64.52, 122.45, 124.96, 125.01, 126.37, 126.44, 126.69, 126.76, 128.44, 128.52, 129.50, 129.45, 129.99, 130.32, 135.74, 135.92, 136.29, 10 o -54- WO 01/90070 PCT/US01/17075 136.23, 152.81, 170.62, 170.65, 170.69, 170.79, 171.60, 201/19, 201.33; 19F NMR (376MHz, d6-DMSO) 8 -226.75, -227.01, -232.90 (bm). [3S/R, (2S)]-3-(1-(3-Trifluoromethylbenzyloxycarbonyl)-1,2,3, 4-tetrahydro-quinolinyl-2-carboxamido) -5-fluoro-4-oxo-pentanoic acid (Example 18) 10 This was prepared from 3-trifluoromethylbenzyl alcohol and (S)-1-(chlorocarbonyl)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid methyl ester [prepared using ' a procedure similar to the one described for the synthesis of (S)-1-.(chlorocarbonyl)-2-piperidinecarboxylic acid 15 methyl ester in EP 75737] using procedures similar to those described above in Methods G, and B-E to produce, after reverse phase HPLC, a white foam (69.2mg, 30%): IR (solid) 1689, 1527, 1393, 1327, 1203, 1165, 1122cm"1; XH NMR (400MHz, d6-DMSO) 8 1.60-1.79 (1H, m) , 2.20-2.39 (1H, 20 m) , 2.40-2.80 (4H, m), 4.10-5.37 (6H, m) , 6.92-7.19 (3H, m) , 7.51-7.76 (4H, m), 8.19-8.74 (1H, m) ; 13C NMR (100MHz, de-DMSO) □ 25.52, 25.63, 27.99, 28.20, 34.55, 34.77, 52.30, 57.84, 57.90, 66.61, 83.05, 83.27, 84.83, 85.04, 123.90, 124.31, 124.35, 124.91, 126.36, 127.75, 129.69, 25 131.81, 131.88, 137.17, 138.02, 138.06, 154.33, 172.02, 172.06, 172.18, 202. 61, 202.75; 19FNMR (376MHz, de-DMSO) 8 -226.84, -227.08, -232.94 (bm). -55- WO 01/90070 PCT/US01/17075 [3S/R, (2S)]-5-Fluoro-3-(1-(3- methylsulphonylbenzyloxycarbonyl)-2-piperidinecarboxamido)-4-oxo-pentanoic acid (Example 19) This was prepared from 3-methylsulfonylbenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a off-white solid (51.7mg, 41% last step) : IR (solid) 1676, 1733, 1787cm"1; ^ NMR 10 (400MHz, de-DMSO) 6 1.1-1.7 (5H, m) , 2.0-2.2 (1H, m) , 2.4-2.9 (3H, m) , 3.1-3.3 (3H, s), 3.8-4.0 (1H, m) , 4.2-4.8 (2.6H, m), 5.0-5.4 (3.4H, m), 7.6-8.0(4H, m), 8.0-8.7 (1H, m) ; X3C NMR (100MHz, dg-DMSO) 5 19.99, 24.61, 27.26, 27.65, 29.36(CH2), 32.86, 34.69 (CH2) , 42.20(CH2), 15 43.77 (CH3) , 47.41,- 47.59, 52.39, 54.50 (2 x CH) , 65.73 (CH2) , 81.53, 83.30, 85.10 (CH2) , 125.84, 126.64, 129.99, 132.69 (ArCH), 138.89, 141.31(ArC), 171.68, 172.07, 172.13, 173.34, 202.65, 202 . 79 (CO) ; 1SF NMR (376MHz, d6~ DMSO) 5 -226.6, -226.8, -230.2, -232.4, -232.4, -232.5, -20 232.6. [3S/R, (2S)]-5-Fluoro-4-oxo-3-(1-(3-phenylbenzyloxycarbonyl)-2-piperidinecarboxamido)-pentanoic acid (Example 20) 5 o o -56- WO 01/90070 PCT/US01/17075 This was prepared from 3-phenylbenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a white powder (105.3mg, 4 6% last step): IR (solid) 1671, 1739cm"1; NMR (400MHz, cfe-DMSO) 6 1.1-5 1.7 (5H, m), 2.0-2.2 (1H, m), 2.5-2.8 (2H, m) , 3.0-3.3 (1H, m), 3.9-4.0 (1H, m), 4.2-4.8 (2.5H, m), 5.0-5.4 (3.5H, m) , 7.2-7.7 (9H, m) , 7.8-8.7 (1H, m) ; 13C NMR (100MHz, d6-DMSO) 8 20.53, 25.14, 27.63, 27.83 (CH2) , 33.32, 35.23 (CH2) , 42.68 (CH2) , 47.90, 48.07, 52.70, 10 52.89, 55.06 (2 x CH) , 67.20 (CH2) , 83.80, 85.61 (CH2) , 126.69, 127.04, 127.37, 127.60, 128.43, 129.82, 129.95, 131.51 (ArCH), 138.39, 138.41, 140.76, 141.18 (ArC), 172.34, 172.47, 172.59, 172.64, 203.26 (CO) ; 19F NMR (376MHz, ds-DMSO) 8 -226.7, -226.8, -230.2, -230.3, -15 232.3, -232.5, -232.5, -232.6. [3S/R, (2S)]-5-Fluoro-3-(1-(3-nitrobenzyloxycarbonyl) -2-piperidirxecarboxamido) -4-oxo-pentanoic acid (Example 21) 20 This was prepared from 3-nitrobenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a off-white solid (35.6mg, 58% last step) : IR (solid) 1671, 1739, 1786cm"1; XH NMR (400MHz, d6-DMSO) 8 1.1-1.7 (5H, m) , 2.0-2.2 (1H, m) , 2.5-2.9 (2H, 25 m), 3.0-3.3 (1H, m) , 3.8-4.0 (1H, m), 4.2-4.8 (2.5H, m), 5.0-5.4 (3.5H, m), 7.6-7.9 (2H, m), 8.1-8.3 (2H, m) , 8.4-8.6 (1H, m) ; 13C NMR (100MHz, ds-DMSO) 8 19.97, 24.46, 27.25, 27.63 (CH2) , 34. 62 (CH2) , 42.20 (CH2) , 47.42, 57 WO 01/90070 PCT/US01/17075 52.16, 52.40, 52.51, 54.55 (2 x CH),, 65.47 (CH2), 83.29, 85.09 (CH2) , 122.26, 122.30, 122.33, 123.06, 130.40, 134.29 (ArCH), 139.51, 139.55, 148.12 (ArC), 112.01 (CO); 19F NMR (376MHz, ds-DMSO) 8 -226.7, -226.8, -226.9, -5 230.2, -230.3, -232.4, -232.6, -232.6, -232.6. [3S/R, (2S)]-5-Fluoro-3~(1-(2,3-dichlorobenzyloxycarbonyl)-2-piperidinecarboxamido)-4-oxo-pentanoic acid (Example 22) 10 This was prepared from 2,3-dichlorobenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a off-white solid (161.2mg, 83% last step) : IR (solid) 1670, 1716, 1739, 1781cm"1; XH NMR (400MHz, ds-DMSO) 8 1.1-1.8 (5H, m) , 2.0-2.2 (1H, m.) , 15 2.5-2.9 (2H, m) , 3.0-3.3 (1H, m), 3.8-4.0 (1H, m) , 4.2-4.8 (2.5H, m), 5.0-5.4 (3.5H, m), 7.3-7.5 (2H, m) , 7.6-7.7 (1H, m) , 7.8-8.7 (1H, m) ; 13C NMR (100MHz, d6-DMSO) 8 20.48, 24.97, 25.14, 27.84, 28.18 (CH2) , 33.41, 35.20 (CH2) , 47.90, 48.07, 52.66, 52.90, 54.86, 55.07 (2 x CH), 20 64.69, 65.04 (CH2) , 82.04, 83.83, 85.62 (CH2) , 128.39, 128.69, 129.19, 130.87 (ArCH), 132.67, 137.66, 137.69, 137.73, 155.58, 156.29 (ArC), 172.17, 172.36, 172.57, 172.63, 173.82, 203.28 (CO) ; 19F NMR (376MHz, ds-DMS0) 8 -226.7, -226.8, -226.9, -230.2, -230.3, -230.4, -232.4, -25 232.5, -232.6, -232.6, -232.7. 58 WO 01/90070 PCT/US01/17075 [3S/R, (2S)]-5-Fluoro~3-(1-(2,5-dichlorobenzyloxycarbonyl)-2-piperidinecarboxamido)-4-oxo-pentanoic acid (Example 23) ci This was prepared from 2,5-dichlorobenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a pale yellow solid (114.6mg, 71% last step) : IR (solid) 1670, 1739, 1782cm"1; 1H NMR (400MHz, de-DMSO) 6 1.1-1.8 (5H, m) , 2.0-2.2 (1H, m) , 2.4-2.9 (2H, m) , 3.0-3.4 (1H, m), 3.8-4.0 (1H, m) , 4.3-4.8 (2.5H, m) , 5.0-5.4 (3.5H, m), 7.3-7.6 (3H, m) , 7.7-8.7 (1H, m); 13C NMR (100MHz, de-DMSO) 5 20.48, 20.77, 24.97, 25.12, 27.61, 27.83, 29. 89 (CH2) , 33.42, 33.50, 35.21 (CH2) , 42.73 (CH2), 47.92, 48.11, 52.71, 52.67, 53.34, 54.88, 55.01, 55.13 (2 x CH), 64.15, 64.30 (CH2) , 82.06, 83.81, 85.61 (CH2), 129.46, 129.83, 130.05, 130.38, 131.80, 131.92 (ArCH), 132.78, 137.16, 137.19 (ArC), 171.65, 172.15, 172.35, 172.59, 173.83, 203.29 (CO) ; 19F NMR (376MHz, de-DMSO) 5 -226.7, -226.8, -226.9, -230.1, -230.3, -232.4, -232.5, -232.5, -232.6. [3S/R, (2S)]-5-Fluoro-4-oxo-3-(1- (2-phenoxybenzyloxycarbonyl)-2-piperidinecarboxamido)-pentanoic acid (Example 24) -59- WO 01/90070 PCT/US01/17075 This was prepared from 3-phenoxybenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give, after reverse phase HPLC, a white powder (20. Omg, 35% last step): XH NMR (400MHz, d6-DMSO) 8 1.19-5 1.52. (5H, m), 2.06 (1H, t), 2.56 (1H, m), 2.78 (1H, m) , 2.99 (1H, m), 3.73 (1H, m), 4.29-5.20 (6H, m) , 7.10-7.48 (9H, m) , 8.10, 8.50 (1H, 2 x d, J" 8.0Hz); 13C NMR (100MHz, de-DMSO) 520.01, 21.52 (CH2) , 24.57 (CH2) , 27.22, 27.60 (CH2), 34.70 (CH2) , 41.98 (CH2) , 52.16, 53.38 (CH) , 54.51, 10 56.05 (CH), 62.32 (CH2) , 83.30 (d, J 178Hz, CH2) , 114.25 (C), 117.13 (C), 118.06 (CH), 119.38, 119.63 (CH), 123.51 (CH), 124.38 (CH), 128.24, 128.27, (C), 129.94, 130.15, 130.35 (CH), 171.63, 171.89 (CO), 172.07, 172.13 (CO) ; 19F NMR (376MHz, ds-DMSO) 8-226.67, -226.80, -232.43, 15 -232.57, -232.63. [3S/R, (25)]-3-(1-(2-Chlorobenzyloxycarbonyl)-1,2,3,4-tetrahydro-quinolinyl-2-carboxamido)-5-fluoro-4-oxo-pentanoic acid (Example 25) This was prepared from 2-chlorobenzyl alcohol and (S)-l-.(chlorocarbonyl) -1,2,3, 4-tetrahydro-quinoline-2-carboxylic acid methyl ester [prepared using a procedure similar to the one described for the synthesis of (S)—1— 25 (chlorocarbonyl)-2-piperidinecarboxylic acid methyl ester described in EP 75737] using procedures similar to those described in Methods G, and B-E to leave a colourless 20 -60- WO 01/90070 PCT/USO1/17075 solid (64mg, 99.3% last step): IR (solid) 1789.2/ 1694.6, 1527.6, 1493.0, 1392.2, 1324.1, 1282.5, 1235.7, 1207.9, 1172.1, 1121.6, 1048.5, 757.3.; *H NMR (400MHz, d6-DMSO) 8 1.75 (1H, m), 2.30 (1H, m) , 2.44-2.88 (4H, m) , 4.15-5.35 5 (6H, m), 7.00 (1H, m) , 7.17 (2H, m), 7.39 (2H, m) , 7.49 (2H, m), 7.70 (1H, m), 8.28+8.68 (1H, 2xm) ; 13C NMR (100MHz, ds-DMSO) □ 24.00, 24.13, 26.47, 26.71, 26.89, 33.12, 33.31 (CH2) , 45.84, 50.82, 56.56 (CH), 63.12, 63.24, 63.36 (CH2) , 82.59 (d, J 177, CH2F), 122.19, 10 122.68, 125.00, 128.76, 128.86, (CH), 130.22, 131.13, 132.35, 132.38135.64, 135.83 (C ), 152.70, 170.40, 170.43, 170.55, 170.59 (C=0), 200.97, 202.10, 201.24 (FCH2C=0) . ) ; 19F NMR (376MHz, d6-DMSO) □□□-226.63 (t, J 45), -226.92 (t, J 45), -230.52 (t, J 45), -232.84 (m) . 15 [3S/R, (2S)]-3- (1-(3-Chlorobenzyloxycarbonyl)-1,2,3,4-tetrahydro-quinolinyl-2-carboxamido)-5-fluoro-4-oxo-pentanolc acid (Example 2 6) 20 This was prepared from 3-chlorobenzyl alcohol and (S)-l-(chlorocarbonyl)-1,2, 3,4-tetrahydro-quinoline-2-carboxylic acid methyl ester [prepared using a procedure similar to the one described for the synthesis of (S)-l-(chlorocarbonyl)-2-piperidinecarboxylic acid methyl ester 25 described in EP 75737] using procedures similar to those described in Methods G, and B-E to produce a colourless solid (124mg, 99.3% last step): IR (solid) 1784.4, 1694.3, 1576.7, 1530.4, 1492.9, 1388.3, 1328.7, 1209.4, O -61- WO 01/90070 PCT/US01/17075 1171.1, 1121.3, 1052.5, 938.5, 768.0.; XH NMR (400MHz, de-DMSO) 5 1.70 (1H, m), 2.33 (1H, m), 2.40-2.85 (4H, m), 4.05-5.30 (6H, m) , 7.02 (1H, m) , 7.18 (2H, m)7.40 (4H, m), 7.71 (1H, m), 8.28+8.70 (1H, 2xm) ; 13C NMR 8 (100MHz, 5 ds-DMSO)25.55, 25.67, 25.76, 28.02, 28.24, 2 8.33,33.04, 33.10, 34.63, 34.82 (CH2), 47.35, 52.06, 52.30, 57.82, 57.89 (CH), 84.11 (d, J 177, CH2F), 123.90, 124.14, 126.40, 126.45, 126.53, 127.63, 127.67, 127.73, 127.79, 128.23, 130.67 (CH), 133.41, 137.19, 139.05, 139.10 (C ), 10 154.19, 154.31, 172.03, 172.07, 172.13, 173.06, 173.20 (C=0), 202.49, 202.63, 202.76 (FCH2C=0) ; 19F NMR (376MHz, de-DMSO) □□□-226.62 (t, J 45), -226.91 (t, J 45), -232.73 (br m) . 15 [3S/R, (2S)]-3-(1-(2-trifluoro methylbenzyloxycarbonyl)-1,2,3, 4-tetrahydro-quinolinyl~2-carboxamido) -5-fluoro-4-oxo-pentanoic acid (Example 27) This was prepared from 2-trifluoromethylbenzyl alcohol 20 and (S)-1-(chlorocarbonyl)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid methyl ester [prepared using a procedure similar to the one described for the synthesis of, (S)-1-(chlorocarbonyl)-2-piperidinecarboxylic acid methyl ester described in EP 75737] using procedures 25 similar to those described in Methods G, and B-E to produce a colourless solid (lOlmg, 95.1% last step): IR (solid) 3308, 1694.4, 1527.1, 1493.3, 1456.7, 1398.4, -62- WO 01/90070 PCT/US01/17075 1314.9, 1209.7, 1168.5, 1118.3, 1052.8, 1039.1, 768.0 cm" 1t XH NMR (400 MHz, CDC13) 5 1.99-3.20 (5H, m), 3.35-5.20 (5.5H, m), 5.30-5.50 (1.5H, m), 6.95-7.35 (6H, m), 7.44-7.78 (3H, m); 13C (100 MHz, d6~DMSO) 6 25.63, 27.96, 34.80 5 (CH2) , 51.98, 57.81 (CH) f 63.70- (CH2), 84.08 (d, CH2F, J 176), 124.58 (q, CF3, J 272), 123.99, 126.29, 126.41, 126.46, 127.81, 127.94, 128.99, 129.02, 130.14 (CH), 134.55, 137.14 (C), 154.13, 171.88, 172.07, 172.12, 202.46, 202.59, 202.72 (C=0) ; 19F NMR (376 MHz, CDCl3) -10 60.17 (s), -230.69 (t, J 48), -231.64 (t, J 48), -231.82 (t, J 48), -232.38 (t, J 48), -232.82 (t, J 48). [3S/R, (2S)]-3-(1-(2-Chlorobenzyloxycarbonyl)-1,2,3,4-tetrahydro-isoquinolinyl-2-carboxamido)-5-fluoro-4-oxo-15 pentanoic acid (Example 2 8) This was prepared from 2-chlorobenzyl alcohol and (S)-l-(chlorocarbonyl)-1, 2, 3, 4-tetrahydro-isoquinoline-2-carboxylic acid methyl ester [prepared using a procedure 20 similar to the one described for the synthesis of (S)-l-(chlorocarbonyl)-2-piperidinecarboxylic acid methyl ester described in EP 75737] using procedures similar to those described in Methods G, and B-E to produce, after reverse phase HPLC, a white foam (57.9mg, 98% last step): IR 25 (solid) 1793, 1680, 1516, 1404, 1337, 1209, 1122, 1055; 1H NMR (400 MHz, d6-DMSO) 5 2.20- 2.80 (2H, m, Asp), 3.00-3.21 (2H, m, CHCH2), 3.84-5.30 (8H, m, NCH2, 0CH2, CH2F, -63- WO 01/90070 PCT/USO1/17075 2xHa), 7.08-7.60 (8H, M, ArH), 8.08-8.63 (1H, m, NH)/ 13C NMR (100MHz, ds-DMSO) 5 30.40, 30.70, 30.85, 33.10, 33.23 (CH2, CHCH2, AspCH2), 43.59, 43.71 (CH2, NCH2), 51.02, 53.17, 53.50, 53.60 (CH, Has), 62.83, 62.91, 63.05 (CH2, 5 OCH2), 81.18, 81.39, 82.96 (CH2, CH2F), 125.86, 126.28, 126.46, 126.66, 128.12, 128.33, 128.67, (CH, ArCH), 131.65, 131.89, 132.02, 132.45, 132.90 (C, ArC), 170.29, 170.60 (C, C=0), 200.81, 200.93 (C, C=0) ; 19F NMR (376MHz, de-DMSO) 8 -226.80, -226.96, -227.04, -232.81, -233.10, -10 233.29, -233.41. [3S/R, (2S)3-3-(1-(Benzyloxycarbonyl)-1,2,3, 4-tetrahydro-isoquinolinyl-2-carboxamido)-5-fluoro-4-oxo-pentanoic acid (Example 29) WO 01/90070 PCT/USO1/17075 [3S/R, (2S)j-5-Fluoro-3-(1-(3- acetamidobenzyloxycarbonyl))-2-piperidinecarboxamido)-4-oxo-pentanoic acid (Example 30) 5 This was prepared from N-(3-hydroxy methylphenyl)acetamide using procedures similar to those described above in Methods G, and B-E to give white solid (26.9mg, 99.2% last step): IR (solid) 1666.3, 1786.9 cm-1; ^ NMR (400MHz, ds-DMSO) 8 1.1-1.8(5H, m, pip)/ 1.9-10 2.2(4H, m, Ac, pip),_2.4-2.9(2H, m, Asp), 3.0-3.6(lH, m, pip), 3.8-4.0(1H, m, pip), 4.2-5.5(6H, m, Asp, pip, -CH2-, -CH2-F), 6.9-7.1(1H, m, Ar), 7.2-7.3 (1H, m, Ar) , 7.4-7.6(2H, m, Ar), 7.8-8.7{lH, m, NH) , 9.9-10.1(lH, br s, NH) ; 13C NMR (100MHz, d6-DMSO) 8 20.02 (CH2, pip), 15 24.35(CH3, Ac), 24.65, 27.33, 42.11(CH2, pip), 54.27, 54.52(CH, Asp, pip), 66.70(CH2, -CH2-Ar), 118 .18, 118.74, 122.34, 129.10(CH, Ar), 137.62, 139.79(C, Ar), 168.71(C, C=0) ; 1SF NMR (376MHz, d6-DMSO) 8 -22 6.7, -232.5 20 [3S/R, (2S)]-5-Fluoro-3-(1-(3-methanesulfonamido) benzyloxycarbonyl)-2-piperidinecarboxamido)-4-oxo-pentanoic acid (Example 31) This was prepared from N-(3-hydroxy methyl-25 phenyl)methanesulfonamide using procedures similar to F o o -65- WO 01/90070 PCT/US01/17075 those described above in Methods G, and B-E to give white solid (35.2mg, 98.7% last step): IR (solid) 1668.0, 1738.4 cm-1; XH NMR (400MHz, d6-DMSO) 5 1.1-1.7 (5H, m, pip), 2.0-2.2(1H, m, pip), 2.5-2.9 (2H, m, Asp), 2.9-5 3.5(4H, m, pip, -S02Me), 3.8-4.0(1H, ra, pip), 4.5-5.5(6H, m, Asp, pip, -CH2-, -CH2-F), 7.0-7.4(4H, m, Ar), 8.0-8.8 (1H, br s, NH) , 9.6-10.0(lH, br s, NH) ; 13C NMR (100MHz, de-DMSO) 8 20.03, 20.14, 24.66, 27.17, 27.32(CH2, pip), 39. 60 (CH3, -S02Me), 42.11(CH2, pip), 54.28, 10 54.46(CH, Asp, pip), 66.34(CH2, -CH2-Ar), 118.44, 119.14, 122.81, 129.74(CH, Ar), 138.48, 138.92(C, Ar), 171.56(C, C=0) ; 19F NMR (376MHz, d6-DMSO) 8 -232.5 [3S/R, (2S)]-5-Fluoro-4-oxo-3-(1-(3-chloro-2-15 thienylmethoxycarbonyl)-2-piperidinecarboxamido)-pentanoic acid (Example 32) This was prepared from 3-chloro-2-thiophenemethanol using procedures similar to those described above in Methods G, 20 and B-E to give a pale cream solid (4.4mg, 98.7% last step): IR (Nicolet Avantar, 360 Omni Sampler, cm-1) 3316, 2951, 1677; XH NMR (400MHz, ds-DMSO) 5 1.21-1.75 (5H, m, CH2pip) , 2.07 (1H, m CH2pip) , 2.67 (1H, m, CH2pip) , 2.82-3.13 (2H, m, CH2Asp), 3.86 (1H, m, CH2), 4.57-5.26 (6H, 25 m) , 7.07 (1H, s, CHthiophene), 7.69 (1H, s, CHthiophene) , 8.44 (1H, d, J 7, NH) ; 13C NMR (100MHz, de-DMSO) 8 19.92 (CH2), 24.46 (CH2), 27.22 (CH2), 34.67 (CH2), 39.13 (CH2), 42.15 (CH2), 52.16, 52.43 (CH, a- -66- WO 01/90070 PCT/US01/17075 CH), 54.53 (CH, a-CH), 59.01 (CH2), 83.25 (d, J 178, CH2F), 124.27 (C), 127.65 (CH), 131.75 (C), 171.56 171.81 (C, CO), 172.07, 172.14 (C, CO); 19F NMR (376MHz, de-DMSO) 5 -226.90,- 232.39, -232.62, -232.69. 2- (l-Carboxymethyl-3-fluoro-2-oxo-propylcarbanioyl) -piperidine-l-carboxylic acid 2,2,2-trifluoro-l-naphthalen-l-yl-ethyl ester (Example 33) 10 This was prepared from (R)-(-)-a-(trifluoromethyl) -naphthyl alcohol (prepared according to Tetrahedron, described above in Methods F, and B-E to give a white solid (176.2mg, 98.1% last step): IR (Solid) 1712.7, 15 1785.8 cm-1; XH NMR(400MHz, d6-DMSO) 5 1.1-1.9 (5H, m, pip), 1.9-2.3(1H, m, pip), 2.5-2.9(2H, m, Asp), 3.0-3.6(1H, m, pip), 4.1-4^-2 (1H, m, pip), 4.3-5.3 (4H, m, Asp, pip, -CH2-F), 7.0-7.1 (1H, m, Ar-CH-), 7.5-8.4(7H, m, Ar) , 8.4-8.8 (1H, m, NH) ); 13C NMR (100MHz, d6-DMSO) 6 20.31, 20 24.86, 25.16, 27.97, 28.25(CH2, pip), 35.22 (CH2, Asp), 43.04(CH2, pip), 52.68, 52.87(CH, Asp), 55.02, 55.21(CH, pip), 69.27, 69.57, 69.92(C, CF3), 83.88, 83.96, 85.65, 85.74(CH2, -CH2-F), 123.35(C, Ar), 124.01, 124.18, 126.09, 126.24, 126.79, 126.97, 127.09, 127.28, 25 127.95(CH, Ar), 128.44, 128.55, 128.94(C, Ar), 129.59, 130.94, 131.01, 131.12(C, Ar), 131.44, 131.52, 133.93, 134.06(C, Ar), 153.71, 154.40, 171.73, 171.87, 171.96, 172.54, 203.20, 203.34(C, C=0) ; 19F NMR (376MHz, ds-DMSO) 1993, 49(9), 1725-1738) using procedures similar to those -67- WO 01/90070 PCT/US01/17075 8 -74.5, -74.6, -74.6, -74.6, -74.8, -74.9, -75.3, -226.5, -226.6, -226.8, -227.0, -230.0, -230.1, -230.2, -232.1, -232.5, -232.5, -232.6. 5 [3S/R, (2S,g-R)]-5-Fluoro-3-(1-(g-trifluoromethyl(3- chloro benzyloxycarbonyl)-2-piperidinecarboxamido)-4-oxo-pentanoic acid (Example 34) ci This was prepared from (R)-(-)-a- (trifluoromethyl)- 3 10 chlorobenzyl alcohol (prepared using procedures from Tetrahedron, 1993, 49(9), 1725-1738)using procedures similar to those described above in Methods F, and B-E to give a white solid (lOlmg, 99%): IR (Solid) 1716.1, 1782.8 cm-1; 1H NMR (400MHz, DMSO) 8 1.1-1.8(5H, m, pip), 15 1.9-2.3(1H, m, pip), 2.4-2.9(2H, m, Asp), 3.0-3.5(1H, m, pip), 3.8-4.1(1H, m, pip), 4.3-5.3(4H, m, Asp, pip, -CH2-F), 6.3-6.5(1H, m, Ar-CH-), 7.3-7.7(4H, m, Ar), 7.7-8.8 (1H, m, NH) ; 13C NMR (100MHz, d6-DMSO) 8 18.25, 18.34, 22.79, 23.08, 25.98, 26.06, 26.22(CH2, pip), 33.20, 20 33.26(CH2, Asp), 41.03(CH2, pip), 45.90, 46.03, 46.29, 50.65, 50.76, 50.92(CH, Asp), 53.07, 53.12, 53.21, 53.27, 53.44, 53.50(CH, pip), 69.87, 69.96, 70.19, 70.52(CH, CF3), 81.49, 81.85, 83.63(CH2, -CH2-F), 117.94, 120.74, 123.53 (C, Ar), 125.09, 125.27, 126.35, 126.57, 128.51, 25 128.57, 128.68, 129.28, 129.33, 129.66(CH, Ar), 132.08, 132.18, 132.64, 132.72, 133.01(C, Ar), 151.54, 151.60, 151.68, 151.93, 152.30, 169.51, 169.72, 169.99, 170.05, 170.17, 170.49, 170.54, 170.61, 171.76, 201.02, 201.16, o 68 WO 01/90070 PCT/US01/17075 201.30 (C, C=0) ; 19F NMR (376MHz, ds-DMSO) 5 -75.4, -75.4, -75.5, -75.6, -75.7, -75.7, -75.7, -75.8, -75.8, -226.6, -226.7, -226.8, -227.0, -230.0, -230.0, -230.1, -232.2, -232.5, -232.6. [3S/R, (2S,g-R) j-5-Fluoro-3-(1-(g-pentafluoromethyl (benzyloxycarbonyl)-2-piperidinecarboxamido)-4-oxo-pentanoic acid (Example 35) This was prepared from (R)-(-)-a- (pentafluoromethyl)-benzyl alcohol (prepared according to Tetrahedron, 1993, 49(9), 1725-1738) using procedures similar to those described above in Methods F, and B-E to give a white 15 solid (59.7mg, 99.2%); IR (Solid) 1721.1, 1736.7 cm-1; 1H NMR (400MHz, DMSO) 5 1.1-1.8(5H, m, pip), 1.9-2.3(1H, m, pip), 2.5-2.9(2H, m, Asp), 3.0-3.5(1H, m, pip), 3.7-4.2 (1H, m, pip), 4.3-5.3(4H, m, Asp, pip, -CH2-F) , 6.2-6.4(1H, m, Ar-CH-), 7.3-7.6(5H, m, Ar), 7.7-8.8(1H, m, 20 NH) ; 13C NMR (100MHz, ds-DMSO) 8 18.14, 18.39, 22.88, 22.99, 26.05, 26.19(CH2, pip), 33.11, 33.22(CH2, Asp), 40.91, 40.95(CH2, pip), 45.85, 46.08, 46.22, 50.57, 50.64, 50.91, 50.98 (CH, Asp), 52.97, 53.13, 53.31(CH, pip), 69.30, 69.39, 69.51, 69.60, 69.70, 69.90, 70.26(CH, 25 C2F5), 79.77, 80.13, 81.52, 81.90, 83.59, 83.72(CH2, -CH2-F), 126.96, 127.08, 127.27, 127.30, 127.54, 128.62, 128.72(CH, Ar), 129.56, 129.86(C, Ar), 151.26, 151.35, 151.61, 152.26, 169.52, 169.65, 169.81, 170.17, 170.22, 10 -69- WO 01/90070 PCT/USO1/17075 170.52, 170.63, 171.66, 171.75, 201.17, 201.31(C, C=0); 19F NMR (376MHz, dg-DMSO) 5 -81.1, -81.2, -81.2, -81.2, -81.3, -81.3, -81.3, -118.4 to -118.6, -119.1 to -119.3, -126.0 to -126.6, -127.0 to -127.4, -226.6, -226.8, -5 226.9, -227.0, -230.0, -230.2, -230.4, -232.0, -232.6, -232.8. [3S/R, (2S,g-R)]-5-Fluoro-3-(1-(g-trifluoromethyl benzyloxycarbonyl-1,2,3, 4-tetrahydro-quinollnyl-2-10 carboxamido)-4-oxo-pentanoic acid (Example 36) This was prepared from (R)-(-)~a- (trifluoromethyl)-benzyl alcohol using procedures similar to those described above in Methods F, and B-E to give a 15 colourless solid (330mg, 98.8%); IR (Solid) 3708.0, 3680.6, 2865.2, 1705.6, 1493.9, 1346.0, 1262.7, 1182.4, 1132.5, 1054.7, 1033.0, 1013.0, 703.8 cm"1; XH NMR (400 MHz, d6-DMSO 5 2.28-2.85 (5H, m) , 4.05-5.20 (5H, m) , 6.45 (1H, m), 6.95-7.32 (3H, m), 7.38-7.75 (6H, m), 8.30-8.85 20 (1H, m) ; 13C NMR 100 MHz, d6-DMSO) 8 25.66, 28.69, 34.93, (CHZ), 47.44, 51.84, 58.07, 72.77 (q, CHCF3, J 120), 84.18 (d, CH2F, J 176), 122.38, 125.17 (C), 126.55, 126.61, 127.89, 128.01, 128.07, 130.14 (CH), 136.68 (C), 171.34, 171.67, 172.01, 173.02, 202.55, 202.67, 202.97 (C=0); 19F 25 NMR. (376MHz, de-DMSO) 6 -74.21 (s) , -226.62 (t, J 48) , -226.99 (t, J 48), -232.67 (br m) . -70- WO 01/90070 PCT/US01/17075 [3S/R, (2S,g-R)]-5-Fluoro-3-(1-(g-trifluoromethyl-(3- . chloro benzyloxycarbonyl-1,2,3,4-tetrahydroquinolinyl-2-carboxamido)-4-oxo-pentanoic acid (Example 37) 5 This was prepared from (R)-(-)-a-(trifluoromethyl)-3-chlorobenzyl alcohol using procedures similar to those described above in Methods F, and B-E to give a colourless solid (323mg 99.1%); IR (solid) 3710.2, 3680.7, 2981.2, 2865.1, 1716.3, 1493.6, 1455.1, 1346.2, 10 1258.1, 1185.7, 1135.3, 1054.8, 1033.0, 1012.9 cm-1; XH NMR (400 MHz, cfe-DMSO) 8 2.20-2.83 (5H, m) , 3.65-5.22 (5H, m) , 5.50 (1H, m) , 6.90-7.30 (3H, m), 7.35-7.75 (5H, m) , 8.25-8.90 (1H, m) ; 13C NMR (100 MHz, d6-DMS0) 8 25.64, 28.33, 33.26, 34.93 (CH2) , 72.23 (q, CHCF3, J 120), 84.14 •15 (d, CHzF, J 176), 122.15, 124.94 (C) , 126.56, 126.62, 126.66, 127.93, 127.99, 130.18, 131.00 (CH), 133.64, 133.92 (C), 171.34, 171.68, 172.00, 173.13, 202.47, 202.62, 202.67, 202.97 (C=0) ; 19F NMR (376 MHz, d6-DMS0) 8 -75.24 (s, CF3) , -226.66 (t, J 48), -227.00 (t, J 48), -20 232.39 (br m).6 -71- WO 01/90070 PCT/US01/17075 2- (l-Carbamoylm.ethyl-3-fluoro-2-oxo-propylcarbamoyl) -piperidine-l-carboxylic acid 3,4-dichloro-benzyl ester (Example 38) ci cr F 5 This was prepared from [3S/R, (2S)]-3-(1-(3,4-Dichlorobenzyloxycarbonyl) -2-piperidinecarboxamido). -5-fluoro-4-oxo-pentanoic acid. 10 Method H Compound 38 To a stirred solution of [3S/R, (2S)]-3-(1-(3,4-Dichlorobenzyloxycarbonyl)-2-piperidinecarboxamido)-5-15 fluoro-4-oxo-pentanoic acid (0.2g, 0.43 mmol) in tetrahydrofuran (THF) (2mL) 0°C was added N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride. A solution of ammonia in dioxane in THF (1.29 mmol) was added to the reaction mixture after it was allowed to 20 warm up to ambient, and the solution was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo. The residue was purified by flash chromatography to give the title compound as a colourless gum (nig) : 1H NMR (400MHz, CDCI3) 5 1.3-1.8(5H, m, pip), 25 2.1-2.5(2H, m, Asp-CH2, pip), 2.6-3.2(2H, m, Asp-CH2, pip), 3.9-5.0(5H, m, Asp-CH, pip-CH, -CH2-F, NH), 5.0-5.2(2H, m, -CH2-Ar), 5.3(0.5H, m, NH), 6.6(0.4H, br s, -72- WO 01/90070 PCT/USO1/17075 NH), 6.8-7.1(1H, m, NH), 7.2(1H, m, Ar) , 7.5(2H, m, Ar); 19F NMR (376MHz, CDC13) 5 -225.0, -225.8, -227.6, -227.9. 2- (l-Ethylcarbamoyliriethyl-3-fluoro-2-oxo-5 propylcarbamoyl)-piperidine-l-carboxylic acid 3,4-dichloro-benzyl ester (Example 39) This was prepared using procedures similar to those 10 described above in Methods H, to give a colourless gum (mg) : 1H NMR (400MHz, CDC13) 8 1.2(3H, m, Et) , 1.3-1.8(5H, m, pip), 2.1-2.5 (2H, m, Asp-CH2, pip), 2.6-3.1(2H, m, Asp-CH2, pip), 3.1-3.5(2H, m, Et), 3.9-4.9(5H, m, Asp-CH, pip-CH, -CH2-F, NH) , 5.0-5.2(2H, m, -CH2-Ar), 6.3-6.7(1H, 15 m, NH) , 7.2 (1H, m, Ar) , 7.4-7.5 (2H, m, Ar) 19F NMR (376MHz, CDC13). 8 -223.4, -226.6, -226.7. 2- (l-Diethylcarbamoylmethyl-3-fluoro-2-oxo-propylcarbamoyl)-piperidine-l-carboxylic acid 3,4-20 dichloro-benzyl ester (Example 40) This was prepared using procedures similar to those described above in Methods H, to give a colourless gum (mg) : 1H NMR (400MHz, CDCI3) 5 1.0-1.3(6H, m, Et) , 1.3-25 1.8 (5H, m, pip), 2.2-2.3(1H, m, pip), 2.7-3.2(2H, m, Asp- -73- WO 01/90070 PCT/USO1/17075 CH2), 3.2-3.4(4H, m, Et) , 4.0-4.3(lH, m, pip), 4..7-5.4(6H, m, -CH2-F, Asp-CH, pip-CH, -CH2-Ar), 7.2(1H, m, Ar), 7.3-7.5(2H, m, Ar) ; 19F NMR (376MHz, CDC13) 5 -232.3, -232.5, -232-9. 2—{1—[(2-Dimethylamino-ethylcarbamoyl)-methyl]-3-fluoro-2-oxo-propylcarbamoyl}-piperidine-l-carboxylic acid 3,4-dichloro-benzyl ester (Example 41) This was prepared using procedures similar to those described above in Methods H, to give a colourless gum (mg) : XH NMR (400MHz, CDC13) 5 1.3-1.8(5H, m, pip), 2.1-2.4(9H, m, -CH2-CH2-N(Me)2), 2.6(1H, m, -CH2-CH2-N(Me)2), 15 2.7-3.1(3H, m, Asp-CH2, pip), 4.0-4.4 (4H, m, -CH2-F, Asp-CH, pip), 4.6-4.7(1H, m, pip-CH), 4.8-4.9(lH, br s, NH) , 5.0-5.2 (2H, m, -CH2-Ar), 6.6-6.7(1H, m, NH), 7.2(1H, m, Ar), 7.5 (2H, m, Ar) ; 19F NMR (376 MHz, CDC13) 6 -222.4. 20 2-{3-Fluoro-l-[2-(4-methyl-piperazin-l-yl)-2-oxo-ethyl]-2-oxo-propylcarbairioyl}-piperidine-l-carboxylic acid 3,4-dichloro-benzyl ester (Example 42) This was prepared using procedures similar to those 25 described above in Methods H, to give a colourless gum 10 o -74- WO 01/90070 PCT/US01/17075 (mg) : XH NMR (400MHz, CDC13) 5 1.3-1.9(5H, m, pip), 2.2-2.5(8H, m, pip), 2.7-3.2(2H, m, Asp-CH2), 3.2-3.3(lH, m, pip), 3.4-3.6(3H, m, pip), 3.6-3.7(1H, m, pip), 4.0-4.3(1H, m, pip), 4.7-5.4(6H, m, Asp-CH, pip-CH, -CH2-Ar, 5 -CH2-F) , 7.2 (1H,. m, Ar) , 7.5(2H, m, Ar) ; 19F NMR (376 MHz, CDC13) 5 -233.5, -233.6, -234.0. [3S/R, (25)]-3- (1- (3,4-Dichlorobenzyloxycarbonyl)-2-piperidinecarboxamido)-5-fluoro-4-oxo-pentanoate, N-(4-10 hydroxy-2-isopropyl disulfanyl-l-methyl-butene)-N-methylformamide ester (Example 43) This was prepared using procedures similar to those 15 described above in Methods H from [3S/R, (2S)]-3-(1-(3,4-Dichlorobenzyloxycarbonyl) -2-piperidinecarboxamido) -5-fluoro-4-oxo-pentanoic acid and N-(4-hydroxy-2-isopropyl disulfanyl-l-methyl-butene) N-methylformamide (Int. J. Pharmaceutics, (1995), 116, 51) to give colourless gum 20 (159_mg, 53%): 1H NMR (400MHz, CDC13) 8 1.1-1.8(11H, m, pip, iPr), 1.8-2.1(3H, m, N-Me), 2.2-2.3(1H, m, pip), 2.7-3.3(9H, m, iPr, -0-CH2-CH2-, Asp-CH2, pip), 4.0-4.3(3H, m, pip, -0-CH2-CH2-), 4.7-5.2(6H, m, -CH2-Ar, -CH2-F, pip, Asp), 6.9-7.1(1H, m, NH), 7.2-7.3(1H, m, Ar), 25 7.4-7.5 (2H, m, Ar)., 7.9-8.0(lH, br s, CHO) ; 19F NMR (376MHz, CDC13) 8 -231.6, -231.7, -231.9. -75- WO 01/90070 PCT/USO1/17075 [3S/R, (2S)]-3- (1- (5-Chloro-2-fluorobenzyloxycarbonyl)-2-piperidinecarboxamido)-5-fluoro-4-oxo-pentanoic acid (Example 44) 5 This was prepared from 5-chloro-2-fluorobenzyl alcohol using procedures similar to those described above in Methods G, and B-E to give a white foam (7.5mg, 99% last step): IR (solid) 1788, 1670, 1491, 1424, 1404, 1250, 10 1178 cm-lcm-1; XH NMR (400MHz, d6-DMSO + TFA) 1.06-1.77 (5H, m) , 1.95-2.20 (1H, m) , 2.28-3.30 (3H, m), 3.75-4.00 (1H, m), 4.20-4.76 (2.5H, m), 4.95-5.35 (3.5H, m), 7.18-7.35 (1H, m), 7.37-7.60 (2H, m), 8.02-8.61 (1H, m); 13C NMR (100MHz, d6"DMS0) 19.94, 20.22, 24.43, 24.56, 27.08, 15 27.28, 27.65, 28.82, 32.87, 34.69, 42.16, 47.38, 47.52, 52.16, 52.38, 54.44, 54.52, 60.37, 60.55, 81.44, 81.51, 83.20, 83.26, 85.03, 103.94, 104.13, 117.47, 117.59, 117.70, 117.78, 126.18, 126.34, 128.57, 128.60, 129.99, 130.22, 155.19, 155.84, 158.01, 158.14, 158.52, 158.89, 20 160.47, 171.14, 171.68, 171.85, 172.08, 172.13, 173.31, 202.55, 202.68; 1SF NMR (376MHz, d6-DMS0 + TFA) 8-120.74, -120.85, -120.89, -120.96, -121.02, -226.68(t), -226. 86 (t) , -226 . 95 (t) , -230.17 (t), -230.44(t), -232.51(t), -232.58(t), -232.61 (t), -232.64(t). 25 Enzyme Assays the cleavage of a fluorogenic substrate by recombinant, The assays for caspase inhibition are based on -76- WO 01/90070 PCT/USO1/17075 purified human Caspases -1, -3, or -8. The assays are run in essentially the same way as those reported by Garcia-.Calvo et al. [J. Biol. Chem. 273 (1998), 32608-32613), using a substrate specific for each enzyme. The substrate 5 for Caspase-1 is Acetyl-Tyr-Val-Ala-Asp-amino-4- methylcoumarin. The substrate for Caspases -3, and -8 is Acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin. particular inhibitor concentration, kobs, is computed by 10 direct fits of the data to the equation derived by Thornberry et al. (Biochemistry 33 (1994), 3943-3939) using a nonlinear least-squares analysis computer program (PRISM 2.0; GraphPad software). To obtain the second order rate constant, kinactj k0bs values are plotted against 15 their respective inhibitor concentrations and kinact values are subsequently calculated by computerized linear regression. Examples 3 and 34 of this invention, and Cbz-Pro-Asp-fmk 20 (WO 91/15557), Cbz-Thz-Asp-fmk (WO 99/477154) and 4-ClCbz-Val-Asp-fmk (WO 00/61542): The observed rate of enzyme inactivation at a Table 2 shows a comparison between compounds of o Cbz-Pro-Asp-fmk Cbz-Thz-Asp-fmk 25 4~ClCbz-Val-Asp-fmk -77- WO 01/90070 PCT/US01/17075 Table 2. C-l, C-3, and C-8 Activity No. Kinact (x 1000 M^s-1) C-l C-3 C-8 . Example 3 318 239.5' 122 Example 34 518 181 839 Cbz-Pro-Asp-fmk 7.5 41.5 15.5 Cb z-Th z-Asp-fmk 227.5 12.5 12 4-ClCbz-Val-Asp-fmk 69 50.5 175 As can be seen from the results in Table 2, the compounds 5 of Example 3 and Example 34 have better activity than Cbz-Pro-Asp-fmk, Cbz-Thz-Asp-fmk and 4-ClCbz-Val-Asp across the range of caspases tested. Inhibition of IL-lft secretion from Mixed Population of 10 Peripheral Blood Mononuclear Cells (PBMC) Processing of pre-IL-l|5 by caspase-1 can be measured in cell culture using a variety of cell sources. Human PBMC obtained from healthy donors provides a mixed population of lymphocyte and mononuclear cells that 15 produce a spectrum of interleukins and cytokines in response to many classes of physiological stimulators. Experimental procedure The test compound is dissolved in Dimethyl 20 Sulphoxide (DMSO,Sigma #D-2650) to give a 100 mM stock solution. This is diluted in complete medium consisting of RPMI containing 10% heat inactivated FCS (Gibco BRL -78- WO 01/90070 PCT/USO1/17075 #10099-141) , 2mM L-Glutamine (Sigma, #G-7513), 100U penicillin and 100 pg/ml streptomycin (Sigma #P-7539). The final concentration range of test compound is from 100 pM down to 6 nM over eight dilution steps. The 5 highest concentration of test compound is equivalent to 0.1% DMSO in the assay. Human PBMC are isolated from Buffy Coats obtained from the blood bank using centrifugation on Ficoll-Paque leukocyte separation medium (Amersham, #17-10 1440-02) and the cellular assay is performed in a sterile 96 well flat-bottomed plate (Nunc). Each well contains 100 ]al of the cell suspension, 1 x 105 cells, 50 p.1 of compound dilutions and 50 p-l of LPS (Sigma #L-3012) at 50 ng/ml final concentration. Controls consist of cells + /-15 LPS stimulation and a serial dilution of DMSO diluted in the same way as compound. The plates are incubated for 16-18h at 37°C in 5% CO2 & 95% humidity atmosphere. After 16-18 h the supernatants are harvested after centrifuging the plates at 100 x g at 18°C for 15 20 min and assayed for their IL-ip content. Measurement of mature IL-lp in the supernatant is performed using the Quantikine kits (R&D Systems) according to manufacturer's instructions. Mature IL-1(3 levels of about 600-1500 pg/ml are observed for PBMCs in positive control wells. 25 The inhibitory potency of the compounds can be represented by an IC50 value, which is the concentration of inhibitor at which 50% of the mature IL-ip is detected in the supernatant as compared to the positive controls. Table 3 shows the inhibition of IL-ip secretion from PBMC 30 for the compounds of Example 3 and Example 5 and the known Cbz-Pro-Asp-fmk and Cbz-Thz-Asp-fmk. -79- WO 01/90070 PCT/US01/17075 Table 3. Inhibition of IL-1[3 secretion from PBMC No. IC50 (nM) Example 3 1150 Example 5 500 Cbz-Pro-Asp-fmk >10000 Cb z - Th z - Asp - fmk 2308 As can be seen from the results in Table 3, the compounds of Example 3 and Example 5 provide much better inhibition 5 of IL-ip secretion from PBMC than does Cbz-Pro-Asp-fmk or Cbz-Thz-Asp-fmk. Hypoxia-induced apoptosis of cortical neurons assay Caspases have been shown to significantly contribute to 10 neuronal cell damage in a number of neurological disorders (Drug News Persp., (2000), 13(1), 5-11). Apoptosis can be induced by growth factor withdrawal and by hypoxia. This assay measures the extent of DNA fragmentation indicating the effectiveness of caspase 15 inhibitors to prevent apoptosis. Experimental procedure Cortical neurons were dissociated from Wistar rat embryos (E17) by a modification of the procedure of Rogers et al 20 1997, Brain Res Bulletin 44:131. Cerebral cortices were isolated aseptically from 15-20 Wistar rat embryos. A cell suspension was prepared by mincing the cerebral cortices and digesting them with papain. Cells were -80- WO 01/90070 PCT/US01/17075 washed with ovomucoid enzyme inhibitor and DNasel and plated onto Poly-D lysine coated plates in high glucose DMEM containing 10% heat-inactivated foetal calf serum, L-glutamine, penicillin and streptomycin. The yield of 5 neurons waslO7 per embryo and they were 80-90% viable as assessed by Trypan blue exclusion. Cells were seeded at lxlO6 cells per cm2 in 96-well plates and cultured in complete medium (in high glucose DMEM containing 10% heat-inactivated foetal calf 10 serum, L-glutamine, penicillin and streptomycin) at 37°C in a normal atmosphere for 48 hours prior to the hypoxia experiments. Hypoxia was performed as described (Tamatani et al.1998, Molecular Brain Research, 58:27). The normal cell medium was replaced by hypoxic medium and cells were 15 incubated in an atmosphere of 95% N2/ 5% C02 for 42 hours. For compound testing, compounds were dissolved in DMSO at lOOmM then diluted in medium and added to the culture at the beginning of the hypoxic period. Apoptosis was measured using an ELISA assay to detect DNA fragmentation 20 (Roche). Controls included cells cultured in aerobic conditions in serum-containing medium. Table 4 shows the activity of the compounds of Example 34 and Example 23 and the known Cbz-Pro-Asp-fmk, Cbz-Thz-Asp-fmk and 4-ClCbz-Val-Asp-fmk in the hypoxia induced apoptosis of 25 cortical neurons assay . -81- </div>

Claims

<div class="application article clearfix printTableText" id="claims"> WO

01/90070 PCT/USO1/17075 Table 4. Activity in the hypoxia induced apoptosis of cortical neurons assay No. IC50 (uM) Example 34 463 Example 23 336 Cbz-Pro-Asp-fmk 2776 Cbz-Thz-Asp-fmk 1563 4-ClCbz-Val-Asp-fmk 1983 As can be seen from the results in Table 4, the compounds 5 of Example 34 and Example 23 are much more potent than Cbz-Pro-Asp-fmk, Cbz-Thz-Asp-fmk and 4-ClCbz-Val-Asp-fmk in the hypoxia induced apoptosis of cortical neurons assay. While we have described a number of embodiments 10 of this invention, it is apparent that our basic examples may be altered to provide other embodiments, which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather 15 than by the specific embodiments, which have been represented by way of example. -82- What is claimed is: 1. A compound of formula I: Ar. YV R3 O R I wherein: Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R1 is hydrogen, CHN2, R, or -CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or an heterocyclylalkyl group; Y is an electronegative leaving group; R2 is C02H, CH2CO2H, or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and R3 is hydrogen, an optionally substituted Ci_6 alkyl, F2, CN, aryl or R3 is attached to Ar to form an unsaturated or partially saturated five or six membered fused ring having 0-2 heteroatoms; provided that if Ring A is unsubstituted piperidine; Ar is unsubstituted phenyl; R2 is CO2H or C02-t-Bu; R3 is H; then R1 is not -CH2- (5-(2, 6-dichlorophenylmehtyl) tetrazol-l-yl.
2 . A compound of formula I: - 83 - wherein: Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R1 is hydrogen, CHN2, R, or -CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or an heterocyclylalkyl group; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and R3 is hydrogen, an optionally substituted Ci_6 alkyl, F2, CN aryl or R3 is attached to Ar to form an unsaturated or partially saturated five or six membered fused ring having 0-2 heteroatoms; provided that: R1 is not - (CH2)n- (Tet) , wherein n is 1-4 and Tet is an optionally substituted tetrazole.
3. A compound of formula i: wherein: Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R1 is -CH2Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or an heterocyclylalkyl group; Y is F, CI, Br, I, arylsulfonyloxy, alkylsulfonyloxy, trifluoromethanesulfonyloxy, OR', SR", -0C=0(R'), -OPO(R4) (R5) , where R' is an aliphatic group, an aryl intellectual property office of n.z 84 - 8 APR 2094 RECEIVED group, an aralkyl group, a carbocyclic group, an alkyl carbocyclic group, a heterocyclic group, or an alkyl heterocyclic group; and R4 and R5 are independently selected from R and OR; R2 is C02H, CH2C02H, or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and R3 is hydrogen, an optionally substituted Ci-6 alkyl, F^, CN, aryl or R3 is attached to Ar to form an unsaturated or partially saturated five or six membered fused ring having 0-2 heteroatoms.
4. The compound of claim 1 having one or more of the following features: (a) R1 is CH2F; (b) R2 is C02H or esters, amides or isosteres thereof; (c) R3 is hydrogen or an optionally substituted Ci-6 alkyl; and (d) Ar is an optionally substituted aryl.
5. The compound of claim 2 having the following features: (a) R1 is CH2F; (b) R2 is C02H or esters, amides or isosteres thereof; (c) R3 is hydrogen or an optionally substituted Ci-6 alkyl; and (d) Ar is an optionally substituted aryl.
6. The compound of claim 3 where Ring A is a piperidine ring.
7 . The compound of claim 3 where Ring A is a tetrahydroquinoline ring. t intellectual'property office of n.z " 85 " - s APR 2004
8. The compound of claim 3 where Ring A is a tetrahydroisoquinoline ring.
9. The compound of claim 1, wherein the compound is selected from the compounds listed in Table 1.
10. A method for treating a condition or disease state in a non-human mammal that is alleviated by treatment with a caspase inhibitor, comprising administering to a non-human mammal in need of such a treatment a therapeutically effective amount of a compound according to any one of claims 1-9.
11. The method of claim 10 wherein the disease is selected from an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs host disease, organ transplant rejection, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic - 8 6 - — intellectual property OFFICE OF N.Z - 8 APR 2004 LLCvI UrM- ruvj»v OFFICE OF N.Z \ nr^riV /CH myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, haemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia,epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, or Japanese encephalitis, various forms of liver disease including alcoholic hepatitis, renal disease, polyaptic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, and meningitis.
12. The method of claim 10 wherein the compound is used to treat complications associated with coronary artery bypass grafts.
13. The method of claim 10 wherein the compound is used for the preservation of cells, said method comprising the step of bathing the cells in a solution of the compound or a pharmaceutically acceptable derivative thereof.
14. The method of claim 10 wherein the compound or a pharmaceutically acceptable derivative thereof is used for an organ transplant or for preserving blood products.
15. The method of claim 10 wherein the compound is used as a component of immunotherapy for the treatment of cancer.
16. A pharmaceutical composition comprising a compound according to any of claims 1-9 and a pharmaceutically acceptable carrier.
17. Use of a compound according to any one of claims 1-9 in the manufacture of a medicament for treating a condition or disease state in mammals that is alleviated by treatment with a caspase inhibitor.
18. The use of claim 17 wherein the disease is selected from an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs host disease, organ transplant rejection, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic " 88 " f intellectual property office of N2 - 8 APR 2004 RECEIVED myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, haemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia,epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, or Japanese encephalitis, various forms of liver disease including alcoholic hepatitis, renal disease, polyaptic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, and meningitis.'
19. The use of claim 17 wherein the compound is used , to treat complications associated with coronary artery bypass grafts.
20. The use according to claim 17, wherein the 1 compound is used for the preservation of cells.
21. The use of claim 20 wherein the compound or a pharmaceutically acceptable derivative thereof is used for an organ transplant or for preserving blood products.
22. The use of claim 17 wherein the compound is used as a component of immunotherapy for the treatment of cancer. -.89 - .■■T-T7»i,nr Iirj, , 11— |TT| i ntellectualproperty" office of n.z - 8 APR 2004
23. A method for the preservation of cells, said method comprising the step of bathing the cells in a solution of a compound according to any one of claims 1-9 or a pharmaceutically acceptable derivative thereof.
24. The method of claim 23 wherein the preservation is in connection with for an organ transplant or for preserving blood products. 90 - 8 APR 2004 </div>